<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26010901</article-id><article-id pub-id-type="pmc">4444267</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0128109</article-id><article-id pub-id-type="publisher-id">PONE-D-14-58149</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Lack of Associations of <italic>CHRNA5-A3-B4</italic> Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking</article-title><alt-title alt-title-type="running-head">Lack of Associations between <italic>CHRNA5-A3-B4</italic> and Smoking Cessation</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tyndale</surname><given-names>Rachel F.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Andy Z. X.</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>George</surname><given-names>Tony P.</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cinciripini</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hawk</surname><given-names>Larry W.</given-names><suffix>Jr.</suffix></name><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Schnoll</surname><given-names>Robert A.</given-names></name><xref ref-type="aff" rid="aff007">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Swan</surname><given-names>Gary E.</given-names></name><xref ref-type="aff" rid="aff008">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Benowitz</surname><given-names>Neal L.</given-names></name><xref ref-type="aff" rid="aff009">
<sup>9</sup>
</xref><xref ref-type="aff" rid="aff010">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Heitjan</surname><given-names>Daniel F.</given-names></name><xref ref-type="aff" rid="aff011">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lerman</surname><given-names>Caryn</given-names></name><xref ref-type="aff" rid="aff007">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><collab>PGRN-PNAT Research Group</collab><xref ref-type="author-notes" rid="fn001">
<sup>&#x000b6;</sup>
</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>Division of Brain &#x00026; Therapeutics, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada</addr-line>
</aff><aff id="aff004">
<label>4</label>
<addr-line>Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America</addr-line>
</aff><aff id="aff005">
<label>5</label>
<addr-line>Department of Psychology, University at Buffalo, State University of New York (SUNY), Buffalo, New York, United States of America</addr-line>
</aff><aff id="aff006">
<label>6</label>
<addr-line>Center for Children and Families, University at Buffalo, State University of New York (SUNY), Buffalo, New York, United States of America</addr-line>
</aff><aff id="aff007">
<label>7</label>
<addr-line>Center for Interdisciplinary Research on Nicotine Addiction, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America</addr-line>
</aff><aff id="aff008">
<label>8</label>
<addr-line>Department of Medicine, Stanford University, Palo Alto, California, United States of America</addr-line>
</aff><aff id="aff009">
<label>9</label>
<addr-line>Department of Medicine, University of California San Francisco, San Francisco, California, United States of America</addr-line>
</aff><aff id="aff010">
<label>10</label>
<addr-line>Department of Bioengineering &#x00026; Therapeutic Sciences, University of California San Francisco, San Francisco, California, United States of America</addr-line>
</aff><aff id="aff011">
<label>11</label>
<addr-line>Department of Biostatistics &#x00026; Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Wei</surname><given-names>Qing-Yi</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Duke Cancer Institute, UNITED STATES</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>Lerman received study medication and placebo, as well as support for medication packaging, from Pfizer. She has also consulted to Gilead, and has been a paid expert witness in litigation against tobacco companies. Cinciripini served on the scientific advisory board of Pfizer Pharmaceuticals, conducted educational talks sponsored by Pfizer on smoking cessation from 2006-2008, and has received grant support from Pfizer. Schnoll received medication and placebo free of charge from Pfizer for a different project, and has consulted to Pfizer and GlaxoSmithKline. George has had both investigator-initiated and industry-sponsored grants from Pfizer in the past 12 months, and serves on a Data Monitoring Committee for Novartis. Benowitz has served as a consultant to several pharmaceutical companies that market smoking cessation medications and has been a paid expert witness in litigation against tobacco companies. Tyndale has acted as a consultant to pharmaceutical companies, primarily on smoking cessation. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The remaining authors report no conflicts of interest.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: RFT AZZ TPG PC LWH RAS GES NLB DJH CL. Performed the experiments: RFT AZZ. Analyzed the data: AZZ DFH. Wrote the paper: RFT AZZ TPG PC LWH RAS GES NLB DJH CL.</p></fn><fn fn-type="other" id="fn001"><p>&#x000b6; Membership of the PGRN-PNAT Research Group is provided in the Acknowledgments.</p></fn><corresp id="cor001">* E-mail: <email>r.tyndale@utoronto.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>5</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>5</issue><elocation-id>e0128109</elocation-id><history><date date-type="received"><day>28</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Tyndale et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Tyndale et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0128109.pdf"/><abstract><p>
<italic>CHRNA5-A3-B4</italic> variants, rs16969968, rs588765 and rs578776, are consistently associated with tobacco consumption among smokers, but the association with smoking cessation is less consistent. Among the studies that reported significant associations with cessation, the effects were observed in smokers treated with placebo treatment in some studies and conversely in those receiving active pharmacological therapy (bupropion and nicotine replacement therapies) in others. Thus, it remains unclear whether <italic>CHRNA5-A3-B4</italic> is a useful marker for optimizing smoking cessation. Using data from 654 Caucasian smokers treated with placebo, nicotine patch or varenicline, we investigated whether <italic>CHRNA5-A3-B4</italic> variants were associated with smoking cessation outcomes, and whether there were significant genotype-by-treatment or haplotype-by-treatment interactions. We observed no significant associations between <italic>CHRNA5-A3-B4</italic> variants and smoking cessation, despite replicating previous associations with baseline tobacco consumption. At end of treatment the effect size on smoking cessation in the placebo, patch and varenicline groups for rs16969968 [GG vs. GA+AA] was OR = 0.66 (P = 0.23), OR = 1.01 (P = 0.99), and OR = 1.30 (P = 0.36) respectively, of rs588765 [CC vs. CT+TT] was OR = 0.96 (P = 0.90), OR = 0.84 (P = 0.58), and OR = 0.74 (P = 0.29) respectively, and for rs578776 [GG vs. GA+AA] on smoking cessation was OR = 1.02 (P = 0.95), OR = 0.75 (P = 0.35), and OR = 1.20 (P = 0.51) respectively. Furthermore, we observed no associations with cessation using the <italic>CHRNA5-A3-B4</italic> haplotype (constructed using rs16969968 and rs588765), nor did we observe any significant genotype-by-treatment interactions, with or without adjusting for the rate of nicotine metabolism (all P&#x0003e;0.05). We also observed no significant genetic associations with 6 month or 12 month smoking abstinence. In conclusion, we found no association between <italic>CHRNA5-A3-B4</italic> variants and smoking cessation rates in this clinical trial; however, as expected, significant associations with baseline tobacco consumption were replicated. Our data suggest that <italic>CHRNA5-A3-B4</italic> gene variants do not exhibit a robust association with smoking cessation and are unlikely to be useful for clinically optimizing smoking cessation pharmacotherapy for Caucasian smokers.</p></abstract><funding-group><funding-statement>This work was supported by a grant from the National Institute on Drug Abuse, the National Cancer Institute, the National Human Genome Research Institute, and the National Institute on General Medical Sciences (U01 DA20830; CL and RFT), funding from the Abramson Cancer Center at the University of Pennsylvania (P30 CA16520; CL), a grant from the Commonwealth of Pennsylvania Department of Health (CL), a grant from the Canadian Institutes of Health Research (CIHR TMH109787), an endowed Chair in Addiction for the Department of Psychiatry (RFT), CAMH foundation (RFT), the Canada Foundation for Innovation (#20289 and #16014), and the Ontario Ministry of Research and Innovation (RFT). No funder had a role in study design, collection and analysis of data, writing of the manuscript, or in the decision to submit this manuscript for review.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="3"/><page-count count="20"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Data are from the PNAT2 study whose authors may be contacted at <email>r.tyndale@utoronto.ca</email> for data requests, pending ethical approval.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Data are from the PNAT2 study whose authors may be contacted at <email>r.tyndale@utoronto.ca</email> for data requests, pending ethical approval.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Smoking is a leading cause of premature death; world-wide about 6 million deaths each year can be attributed to smoking [<xref rid="pone.0128109.ref001" ref-type="bibr">1</xref>]. Compared to never smokers, smokers&#x02019; life expectancy is reduced by an average of 10 years [<xref rid="pone.0128109.ref002" ref-type="bibr">2</xref>]. Nicotine is the main psychoactive component of tobacco and exerts its pharmacological effects by its actions on the nicotinic acetylcholine receptors [<xref rid="pone.0128109.ref003" ref-type="bibr">3</xref>]. Genetic variants in <italic>CHRNA5-A3-B4</italic>, encoding the &#x003b1;5, &#x003b1;3, and &#x003b2;4 nicotinic acetylcholine receptor subunits, are robustly associated with smoking behaviors such as cigarettes smoked per day and nicotine dependence, as well as risks for smoking-related diseases, including lung cancer and chronic obstructive pulmonary disease [<xref rid="pone.0128109.ref004" ref-type="bibr">4</xref>&#x02013;<xref rid="pone.0128109.ref010" ref-type="bibr">10</xref>]. Genetic mapping studies indicate that three independent loci within <italic>CHRNA5-A3-B4</italic> are associated with cigarette consumption and nicotine dependence in Caucasians [<xref rid="pone.0128109.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0128109.ref012" ref-type="bibr">12</xref>]. These independent loci can be represented by rs16969968 and correlated SNPs (sometimes referred to as &#x0201c;Bin A&#x0201d; or &#x0201c;Locus 1&#x0201d;), rs588765 and correlated SNPs (sometimes referred to as &#x0201c;Bin B&#x0201d; or &#x0201c;Locus 3&#x0201d;), and rs578776 and correlated SNPs (sometimes referred to as &#x0201c;Bin C&#x0201d; or &#x0201c;Locus 2&#x0201d;). The impact of these independent loci on cigarette consumption and nicotine dependence has been consistently replicated, but whether these variants also predict smoking cessation outcomes is less clear and is the focus of this investigation [<xref rid="pone.0128109.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0128109.ref012" ref-type="bibr">12</xref>].</p><p>Smoking cessation at any age has tremendous health benefits. Smokers who had quit smoking at 30, 40 and 50 years of age gained an average of 10, 9, and 6 years of life, respectively, when compared with those who continued to smoke [<xref rid="pone.0128109.ref002" ref-type="bibr">2</xref>]. Yet despite the substantial health benefits, only 3% of all smokers are able to quit smoking each year [<xref rid="pone.0128109.ref003" ref-type="bibr">3</xref>]. Of the three FDA-approved smoking cessation treatments [<xref rid="pone.0128109.ref001" ref-type="bibr">1</xref>], transdermal nicotine patch delivers nicotine to reduce craving and withdrawal in smokers to promote smoking cessation. It is a commonly used treatment with few side effects, but it has modest clinical efficacy. Varenicline, a partial agonist for the &#x003b1;4&#x003b2;2 nicotinic receptor and a full agonist for the &#x003b1;7 nicotinic receptor [<xref rid="pone.0128109.ref013" ref-type="bibr">13</xref>], appears to have the greatest clinical efficacy, but it has more side effects, such as nausea, which can lead to discontinuation of use. Substantial individual variability is observed in both clinical efficacy and in side effects within each type of smoking cessation treatment; genetics could contribute to this variability [<xref rid="pone.0128109.ref014" ref-type="bibr">14</xref>&#x02013;<xref rid="pone.0128109.ref016" ref-type="bibr">16</xref>]. The estimated heritability of smoking cessation is 50&#x02013;58% indicating that genetic factors are important determinants of cessation [<xref rid="pone.0128109.ref014" ref-type="bibr">14</xref>, <xref rid="pone.0128109.ref017" ref-type="bibr">17</xref>]. Genetically tailored drug therapy could assist in maximizing smoking cessation efficacy. For example, the Pharmacogenomics of Nicotine Dependence Treatment (PNAT) clinical trial demonstrated that varenicline was more efficacious than nicotine patch for smokers with genetically normal rates of nicotine metabolism, while the efficacy was equivalent for smokers with genetically slower rates of nicotine metabolism. Smokers with slower rates of nicotine metabolism (vs. smokers with normal rate of nicotine metabolism) also had higher overall side-effect severity when taking varenicline in comparison to placebo; together this suggests that normal metabolizers should be treated with varenicline, while slow metabolizers should be treated with nicotine patch [<xref rid="pone.0128109.ref018" ref-type="bibr">18</xref>].</p><p>A number of studies have investigated the association between <italic>CHRNA5-A3-B4</italic> gene variants and smoking cessation with inconsistent results. Some studies observed significant associations between <italic>CHRNA5-A3-B4</italic> gene variants and smoking cessation [<xref rid="pone.0128109.ref019" ref-type="bibr">19</xref>&#x02013;<xref rid="pone.0128109.ref023" ref-type="bibr">23</xref>], while other studies did not [<xref rid="pone.0128109.ref024" ref-type="bibr">24</xref>&#x02013;<xref rid="pone.0128109.ref029" ref-type="bibr">29</xref>], and a large genome-wide association study did not find a significant association between <italic>CHRNA5-A3-B4</italic> gene variants and smoking status (i.e. current versus former smokers) [<xref rid="pone.0128109.ref005" ref-type="bibr">5</xref>]. Even among those studies reporting a significant association between <italic>CHRNA5-A3-B4</italic> gene variants and smoking cessation, it is not clear whether the <italic>CHRNA5-A3-B4</italic> SNPs have a general effect on smoking cessation, which is independent of the specific type of pharmacological treatment (i.e., would alter all active treatments), or whether they alter the efficacy of a specific treatment arm (i.e. only nicotine patch or placebo). For example, Chen and colleagues reported that the association between a <italic>CHRNA5-A3-B4</italic> haplotype, the rs16969968_rs588765, consisting of rs16969968 (Bin A) and rs680244/rs588765 (Bin B), and smoking cessation was primarily observed among smokers treated with placebo; and that this association was mitigated by active pharmacological therapy [<xref rid="pone.0128109.ref030" ref-type="bibr">30</xref>]. In contrast, Munaf&#x000f2; and colleagues reported a significant association between <italic>CHRNA5-A3-B4</italic> variant rs1051730 (Bin A) and smoking cessation outcomes in smokers who were receiving nicotine replacement therapy, with little effect observed in those receiving placebo treatment [<xref rid="pone.0128109.ref021" ref-type="bibr">21</xref>]. Another recent study reported a significant treatment (placebo vs. nicotine replacement therapy) by genotype (rs1051730) interaction on smoking cessation outcomes [<xref rid="pone.0128109.ref031" ref-type="bibr">31</xref>].</p><p>The objective of this study was to investigate the association between <italic>CHRNA5-A3-B4</italic> gene variants and the clinical efficacy (i.e. smoking cessation outcomes) associated with treatment with placebo, nicotine patch or varenicline. This pharmacogenomics trial is the first to compare the impact of <italic>CHRNA5-A3-B4</italic> gene variants on smoking cessation outcomes in these two widely used treatments head-to-head while including a double-dummy placebo controlled design. Further, the placebo treatment arm (N = 212) is larger than that included in the prior report identifying significant associations with <italic>CHRNA5-A3-B4</italic> gene variants and smoking cessation under placebo treatment (N = 132)[<xref rid="pone.0128109.ref030" ref-type="bibr">30</xref>]. If these SNPs are validated in the current trial as significantly associated with an active treatment, it could be possible to optimize the choice of pharmacotherapy for individual smokers based on genotype or haplotype. We first sought to confirm the significant effect of the <italic>CHRNA5-A3-B4</italic> variants on baseline smoking behaviors in the screened Caucasian population (N = 1026), and then to investigate the association between these <italic>CHRNA5-A3-B4</italic> SNPs and smoking cessation in 654 Caucasian smokers randomized to placebo, nicotine patch or varenicline. We focused on the Caucasians participants of the clinical trial in this analysis to minimize population stratification.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><sec id="sec003"><title>Participants and procedures</title><p>Smokers were recruited into a placebo-controlled clinical trial through advertisements for a free smoking cessation program. The primary findings of this clinical trial were recently published [<xref rid="pone.0128109.ref018" ref-type="bibr">18</xref>]. The study consisted of three treatment arms: (1) nicotine patch (placebo pill/active patch); (2) varenicline (active pill/placebo patch); and (3) placebo (placebo pill/placebo patch). The present genetic analyses were restricted to Caucasian smokers to minimize population stratification as the frequency of these variants varies substantially between world populations. Caucasian smokers (N = 1026) were screened for their rate of nicotine metabolism (based on their nicotine metabolite ratio) and baseline smoking phenotypes. Of this group, 654 Caucasian smokers were randomized into the three treatment arms with slow metabolizers oversampled to assess the influence of nicotine metabolism on smoking cessation [<xref rid="pone.0128109.ref018" ref-type="bibr">18</xref>]. The over-sampling of smokers with slow nicotine metabolism is unlikely to introduce bias into our analyses of <italic>CHRNA5-A3-B4</italic> and smoking cessation since the allele frequencies of the <italic>CHRNA5-A3-B4</italic> SNPs observed in this study were very similar to allele frequencies reported by previous studies in Caucasians as well as by the 1000 genome project (see <xref rid="sec009" ref-type="sec">results</xref>) [<xref rid="pone.0128109.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0128109.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0128109.ref030" ref-type="bibr">30</xref>]. Furthermore, the gene encoding for the main nicotine metabolizing enzyme, CYP2A6, is on a different chromosome than <italic>CHRNA5-A3-B4</italic>, and is thus unlikely to have any linkage equilibrium relationship with <italic>CHRNA5-A3-B4</italic>. There was also little difference in the results with or without adjusting for the rate of nicotine metabolism in any of the smoking cessation models.</p><p>The clinical trial was conducted at four academic medical centers (University of Pennsylvania, Centre for Addiction and Mental Health/University of Toronto, State University of New York at Buffalo, and MD Anderson Cancer Center). Eligible participants were 18&#x02013;65 years old and reported smoking &#x02265; 10 cigarettes per day for &#x02265; 6 months (verified by carbon monoxide (CO) &#x0003e; 10ppm). Exclusion criteria included use of non-cigarette tobacco products; history of substance abuse treatment (other than nicotine); consumption of more than 25 standard alcohol drinks per week; history of DSM-IV Axis 1 psychiatric disorder or suicide risk score on the MINI International Neuropsychiatric Interview; history of cancer, kidney or liver diseases; history of clinically significant cardiac dysrhythmias, stroke, angina, heart attack, or uncontrolled hypertension; use of smoking cessation medication within the last 14 days; current use of anti-psychotics, stimulants, opiate medications, anti-coagulants, rescue inhalers, or antiarrhythmics; and pregnancy/lactation. The study protocol has been published previously [<xref rid="pone.0128109.ref018" ref-type="bibr">18</xref>]. Briefly, intention-to-treat smokers were randomly assigned by baseline NMR status to 11 weeks of placebo (placebo pill plus placebo patch), 21 mg nicotine patch (active patch plus placebo pill), or 1 mg varenicline (active pill plus placebo patch), plus behavioral counselling. The primary endpoint was biochemically verified 7 day point prevalence abstinence at the end of treatment to estimate the pharmacological effect of treatment by NMR. All participants provided written informed consent in accordance with the principles expressed in the Declaration of Helsinki, and the study protocol was approved by the institutional review boards of University of Pennsylvania, University of Toronto, State University of New York at Buffalo, and MD Anderson Cancer Center.</p></sec><sec id="sec004"><title>Smoking abstinence</title><p>Biochemically verified 7-day point prevalence abstinence was assessed at end of treatment (EOT, week 11), 6 months and 12 months. Point prevalence abstinence is defined as no-self-reported smoking (not even a puff) for at least 7 days and was verified by exhaled carbon monoxide levels &#x0003c; 8 ppm [<xref rid="pone.0128109.ref032" ref-type="bibr">32</xref>]. We focused on the EOT time point in the present study as we were interested in the pharmacogenetic effect of <italic>CHRNA5-A3-B4</italic> variants on smoking cessation, which is strongest during treatment; as in most pharmacogenomics studies this was the primary time point used for analysis of these gene variants [<xref rid="pone.0128109.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0128109.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0128109.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0128109.ref031" ref-type="bibr">31</xref>]; we have also included 6 month and 12 month smoking abstinence association data in supplementary materials. All statistical analyses on smoking cessation were performed on an intent-to-treat basis; subjects lost during follow-up were considered as smokers [<xref rid="pone.0128109.ref032" ref-type="bibr">32</xref>].</p></sec><sec id="sec005"><title>Genotyping</title><p>A total of 1026 DNA samples were extracted from blood. The <italic>CHRNA5-A3-B4</italic> SNPs were genotyped using ABI Viia 7 real time PCR machine (Applied Biosystems, Foster City, CA). The genotyping reaction was performed with 2.5 &#x003bc;L TaqMan GTXpress master mix and 2.5 &#x003bc;L of water containing 10 ng of DNA and 0.0625 &#x003bc;L of 80x Taqman SNP genotyping probes (rs16969968: C__26000428_20, rs588765: C____18826_10 and rs578776: C____721253_10, Applied Biosystems, Foster City, CA). The allele discrimination data were analyzed using Viia 7 software version 1.2. All genotyping results included in our analyses had call quality values &#x0003e;0.985. For quality control (QC) all samples were genotyped again using a second independent DNA sample for two high allele frequency variants (rs16969968 &#x00026; rs588768), and ~18% of the samples (n = 180) were also re-genotyped for rs578776. The concordance rates for all SNPs between the original genotyping and the QC genotyping were 100%.</p><p>PLINK was used to estimate <italic>CHRNA5-A3-B4</italic> haplotype (rs16969968 and rs588765) probabilities for each individual (using the&#x02014;hap-phase-wide option) as described previously [<xref rid="pone.0128109.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0128109.ref033" ref-type="bibr">33</xref>]. The posterior probability for the haplotypes was 1 for more than 99% of the haplotypes. The haplotypes were assumed to be &#x02018;additive&#x02019; [<xref rid="pone.0128109.ref030" ref-type="bibr">30</xref>].</p></sec><sec id="sec006"><title>Nicotine metabolism</title><p>This clinical trial was design to prospectively assess the impact of nicotine metabolism on smoking cessation outcomes. The rate of nicotine metabolism was assessed in a baseline blood sample by the nicotine metabolite ratio (NMR; 3&#x02019;hydroxycotinine/cotinine). NMR is highly reproducible in regular smokers, shows little temporal fluctuation due to the long half-life of cotinine (16 hours) [<xref rid="pone.0128109.ref034" ref-type="bibr">34</xref>, <xref rid="pone.0128109.ref035" ref-type="bibr">35</xref>], and is not influenced by variation in other cotinine or 3-hydroxycotinine metabolizing genes, but rather exclusively by CYP2A6 [<xref rid="pone.0128109.ref036" ref-type="bibr">36</xref>]. The NMR used to distinguish slow metabolizers from normal metabolizers was 0.31 based on the stratification performed in the parent clinical trial [<xref rid="pone.0128109.ref018" ref-type="bibr">18</xref>]. Individuals with slower rates of nicotine metabolism were over-sampled to increase statistical power, therefore, in the current analyses we performed analyses with and without adjusting for the rate of nicotine metabolism (as a covariate) in all the smoking cessation models. Thus these models examined both the role of the nicotinic receptor variants alone, and with the CYP2A6 phenotype as previously described [<xref rid="pone.0128109.ref037" ref-type="bibr">37</xref>]. Additional baseline measures assessed included self-report cigarettes per day, cotinine levels, derived cotinine per cigarette and Fagerstrom test for nicotine dependence (FTND).</p></sec><sec id="sec007"><title>Analytical chemistry</title><p>Concentrations of cotinine and 3-HC were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described previously [<xref rid="pone.0128109.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0128109.ref039" ref-type="bibr">39</xref>]. Briefly, 100 &#x003bc;L biological samples were extracted using a liquid-liquid extraction with cotinine-d<sub>3</sub> and 3-hydroxycotinine-d<sub>3</sub> as the internal standards. The evaporated extract was reconstituted in 100 &#x003bc;L of 100 mM aqueous ammonium acetate: methanol (v/v 80:20) with 1% acetic acid [<xref rid="pone.0128109.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0128109.ref039" ref-type="bibr">39</xref>]. The chromatography was carried out using a Synergi Polar RP column (150 x 4.6 mm I.D.; particle size 4 micron). A linear gradient of 10 mM ammonium acetate/0.1% acetic acid in water (solvent A) and 10 mM ammonium acetate/0.1% acetic acid in methanol (solvent B) was used as the mobile phase [<xref rid="pone.0128109.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0128109.ref039" ref-type="bibr">39</xref>]. At a flow rate of 0.7 ml/min. 3-HC and cotinine eluted at 5.3 and 6.2 min, respectively. Calibration standards were prepared in the range of 1 to 1000 ng/mL, unlabeled standards were plotted against fixed concentration (20 ng/ml) of corresponding labeled internal standard. The plots were linear for cotinine and 3HC with r<sup>2</sup> &#x0003e; 0.99 for both. Cotinine&#x02019;s molecular weight is 176.21g/mol. Thus, 1 ng/ml cotinine = 5.67 nmol/L.</p></sec><sec id="sec008"><title>Statistical analyses</title><p>Baseline demographic variables among the total screened population were compared between <italic>CHRNA5-A3-B4</italic> genotypes using Mann-Whitney tests, Kruskal&#x02013;Wallis tests, or Chi-square tests. The associations between dichotomized <italic>CHRNA5-A3-B4</italic> SNPs rs16969968 (G/G = 0 and G/A and A/A = 1), rs588765 (C/C = 0 and C/T and T/T = 1), and rs578776 (A/A = 0 and A/G and G/G = 1) and smoking abstinence were evaluated using logistic regression among the intent to treat population. All smoking cessation models were adjusted for age, gender and rate of nicotine metabolism as covariates (see figure legends for details). The <italic>CHRNA5-A3-B4</italic> haplotypes were dummy coded (i.e., each individual would have variables for haplotype 1, haplotype 2 and haplotype 3). Statistical analyses were performed using Stata 12 (StataCorp, College Station, TX).</p></sec></sec><sec sec-type="results" id="sec009"><title>Results</title><sec id="sec010"><title>Descriptive data of the study participants</title><p>Demographic data for the screened population are presented in <xref rid="pone.0128109.t001" ref-type="table">Table 1</xref>. The study participants smoked on average 20.2 cigarettes per day, and 43% of the study participants were female. Smokers with a slower rate of nicotine metabolism (i.e., NMR&#x0003c;0.31) smoked 19.1 cigarettes per day (95% CI = 18.4&#x02013;19.8), whereas smokers with a normal rate of nicotine metabolism smoked 20.6 cigarettes per day (95% CI = 20.0&#x02013;21.2, P = 0.004). All three genotyped <italic>CHRNA5-A3-B4</italic> SNPs were in Hardy-Weinberg equilibrium (all P&#x0003e;0.05, <xref rid="pone.0128109.t001" ref-type="table">Table 1</xref>). The SNPs rs16969968, rs588765 and rs578776 had minor allele frequencies of 39.3%, 40.0% and 25.0% respectively in the screened population (N = 1026), which were very similar to 37.3%, 41.7% and 25.2% in the intent-to-treat participants (N = 654). These allele frequencies were also very similar to published frequencies in Caucasians (e.g. Saccone et al., 2010 reported 42%, 39% and 24% respectively [<xref rid="pone.0128109.ref012" ref-type="bibr">12</xref>], and the 1000 genome project reported 41.7%, 39.2% and 24.2% respectively) [<xref rid="pone.0128109.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0128109.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0128109.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0128109.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0128109.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0128109.ref040" ref-type="bibr">40</xref>]. <italic>CHRNA5-A3-B4</italic> haplotypes were constructed using rs16969968 and rs588765 [<xref rid="pone.0128109.ref030" ref-type="bibr">30</xref>]. In this study, the rs16969968_rs588765 haplotype frequencies were G_C 20.9%, G_T 40.0%, and A_C 39.2%, which is very similar to the 20.8%, 43.7% and 35.5% reported previously [<xref rid="pone.0128109.ref030" ref-type="bibr">30</xref>]. Those were labeled haplotype 1, haplotype 2, and haplotype 3 respectively [<xref rid="pone.0128109.ref030" ref-type="bibr">30</xref>].</p><table-wrap id="pone.0128109.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128109.t001</object-id><label>Table 1</label><caption><title>Baseline demographics and smoking behaviors in the screened population (N = 1026).</title></caption><alternatives><graphic id="pone.0128109.t001g" xlink:href="pone.0128109.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td colspan="5" align="center" rowspan="1">
<bold>RS16969968</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>GG</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>GA</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>AA</bold>
</td><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>n</italic> (screened)<xref rid="t001fn001" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">370</td><td align="left" rowspan="1" colspan="1">506</td><td align="left" rowspan="1" colspan="1">150</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cigarettes per day</td><td align="left" rowspan="1" colspan="1">19.8 (18.9&#x02013;20.7)</td><td align="left" rowspan="1" colspan="1">20.2 (19.6&#x02013;20.9)</td><td align="left" rowspan="1" colspan="1">21.0 (19.2&#x02013;22.2)</td><td align="left" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" rowspan="1" colspan="1">CO levels *only ITT</td><td align="left" rowspan="1" colspan="1">23.5 (22.2&#x02013;24.8)</td><td align="left" rowspan="1" colspan="1">25.8 (24.5&#x02013;27.0)</td><td align="left" rowspan="1" colspan="1">24.9 (22.4&#x02013;27.3)</td><td align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Cotinine (ng/mL)&#x000a0;</td><td align="left" rowspan="1" colspan="1">219.6 (209.4&#x02013;229.8)</td><td align="left" rowspan="1" colspan="1">242.0 (232.3&#x02013;251.6)</td><td align="left" rowspan="1" colspan="1">269.0 (252.5&#x02013;285.4)</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">3'-Hydroxycotinine (ng/mL)&#x000a0;</td><td align="left" rowspan="1" colspan="1">91.0 (84.9&#x02013;97.1)</td><td align="left" rowspan="1" colspan="1">93.7 (88.9&#x02013;98.5)</td><td align="left" rowspan="1" colspan="1">116.4 (104.3&#x02013;128.5)</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Sum of Cotinine and 3'-Hydroxycotinine (ng/mL)</td><td align="left" rowspan="1" colspan="1">311.1 (296.3&#x02013;325.8)</td><td align="left" rowspan="1" colspan="1">336.1 (322.8&#x02013;349.3)</td><td align="left" rowspan="1" colspan="1">385.3 (359.7&#x02013;411.0)</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">FTND</td><td align="left" rowspan="1" colspan="1">5.2 (5.0&#x02013;5.4)</td><td align="left" rowspan="1" colspan="1">5.4 (5.1&#x02013;5.8)</td><td align="left" rowspan="1" colspan="1">5.4 (5.1&#x02013;5.8)</td><td align="left" rowspan="1" colspan="1">0.23</td></tr><tr><td align="left" rowspan="1" colspan="1">NMR</td><td align="left" rowspan="1" colspan="1">0.42 (0.40&#x02013;0.45)</td><td align="left" rowspan="1" colspan="1">0.40 (0.39&#x02013;0.42)</td><td align="left" rowspan="1" colspan="1">0.43 (0.40&#x02013;0.47)</td><td align="left" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (% Female)</td><td align="left" rowspan="1" colspan="1">41%</td><td align="left" rowspan="1" colspan="1">44%</td><td align="left" rowspan="1" colspan="1">42%</td><td align="left" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (Years)</td><td align="left" rowspan="1" colspan="1">46.3 (45.2&#x02013;47.5)</td><td align="left" rowspan="1" colspan="1">46.1 (45.1&#x02013;47.1)</td><td align="left" rowspan="1" colspan="1">44.8 (42.8&#x02013;46.7)</td><td align="left" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (Kg/m2)</td><td align="left" rowspan="1" colspan="1">29.1 (28.5&#x02013;29.7)</td><td align="left" rowspan="1" colspan="1">28.4 (27.9&#x02013;28.9)</td><td align="left" rowspan="1" colspan="1">29.5 (28.4&#x02013;30.6)</td><td align="left" rowspan="1" colspan="1">0.08</td></tr><tr><td colspan="5" align="center" rowspan="1">
<bold>RS588765</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>CC</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>CT</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>TT</bold>
</td><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>n</italic> (screened)<xref rid="t001fn002" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">360</td><td align="left" rowspan="1" colspan="1">511</td><td align="left" rowspan="1" colspan="1">155</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cigarettes per day</td><td align="left" rowspan="1" colspan="1">20.5 (19.6&#x02013;21.2)</td><td align="left" rowspan="1" colspan="1">20.2 (19.4&#x02013;20.9)</td><td align="left" rowspan="1" colspan="1">19.6 (18.6&#x02013;20.6)</td><td align="left" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">CO levels *only ITT</td><td align="left" rowspan="1" colspan="1">25.4 (23.9&#x02013;26.9)</td><td align="left" rowspan="1" colspan="1">24.7 (23.5&#x02013;25.8)</td><td align="left" rowspan="1" colspan="1">24.0 (21.9&#x02013;26.1)</td><td align="left" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1">Cotinine (ng/mL)</td><td align="left" rowspan="1" colspan="1">243.8 (232.9&#x02013;254.6)</td><td align="left" rowspan="1" colspan="1">238.7 (229.2&#x02013;248.2)</td><td align="left" rowspan="1" colspan="1">220.7 (204.9&#x02013;236.6)</td><td align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">3'-Hydroxycotinine (ng/mL)&#x000a0;</td><td align="left" rowspan="1" colspan="1">99.7 (93.2&#x02013;106.3)</td><td align="left" rowspan="1" colspan="1">96.2 (90.9&#x02013;101.4)</td><td align="left" rowspan="1" colspan="1">86.9 (78.7&#x02013;95.2)</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Sum of Cotinine and 3'-Hydroxycotinine (ng/mL)</td><td align="left" rowspan="1" colspan="1">344.2 (328.4&#x02013;360.1)</td><td align="left" rowspan="1" colspan="1">335.3 (321.9&#x02013;348.7)</td><td align="left" rowspan="1" colspan="1">307.7 (285.6&#x02013;329.7)</td><td align="left" rowspan="1" colspan="1">
<bold>0.04</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">FTND</td><td align="left" rowspan="1" colspan="1">5.4 (5.1&#x02013;5.6)</td><td align="left" rowspan="1" colspan="1">5.3 (5.1&#x02013;5.5)</td><td align="left" rowspan="1" colspan="1">5.3 (5.0&#x02013;5.6)</td><td align="left" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">NMR</td><td align="left" rowspan="1" colspan="1">0.41 (0.39&#x02013;0.43)</td><td align="left" rowspan="1" colspan="1">0.42 (0.40&#x02013;0.44)</td><td align="left" rowspan="1" colspan="1">0.41 (0.37&#x02013;0.44)</td><td align="left" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (% Female)</td><td align="left" rowspan="1" colspan="1">40%</td><td align="left" rowspan="1" colspan="1">46%</td><td align="left" rowspan="1" colspan="1">38%</td><td align="left" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (Years)</td><td align="left" rowspan="1" colspan="1">46.3 (45.1&#x02013;47.4)</td><td align="left" rowspan="1" colspan="1">46.2 (45.2&#x02013;47.2)</td><td align="left" rowspan="1" colspan="1">44.5 (42.8&#x02013;46.3)</td><td align="left" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (Kg/m2)</td><td align="left" rowspan="1" colspan="1">29.0 (28.4&#x02013;29.6)</td><td align="left" rowspan="1" colspan="1">28.6 (28.1&#x02013;29.1)</td><td align="left" rowspan="1" colspan="1">29.2 (28.2&#x02013;30.1)</td><td align="left" rowspan="1" colspan="1">0.41</td></tr><tr><td colspan="5" align="center" rowspan="1">
<bold>RS578776</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<bold>GG</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>GA</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>AA</bold>
</td><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>n</italic> (screened)<xref rid="t001fn003" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">572</td><td align="left" rowspan="1" colspan="1">396</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cigarettes per day</td><td align="left" rowspan="1" colspan="1">20.3 (19.7&#x02013;20.9)</td><td align="left" rowspan="1" colspan="1">19.9 (19.1&#x02013;20.7)</td><td align="left" rowspan="1" colspan="1">20.7 (18.4&#x02013;23.1)</td><td align="left" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">CO levels *only ITT</td><td align="left" rowspan="1" colspan="1">24.8 (23.6&#x02013;25.9)</td><td align="left" rowspan="1" colspan="1">24.8 (23.5&#x02013;26.1)</td><td align="left" rowspan="1" colspan="1">25.1 (20.3&#x02013;29.8)</td><td align="left" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">Cotinine (ng/mL)</td><td align="left" rowspan="1" colspan="1">246.4 (237.3&#x02013;255.4)</td><td align="left" rowspan="1" colspan="1">230.9 (220.9&#x02013;40.9)</td><td align="left" rowspan="1" colspan="1">200.7 (176.3&#x02013;224.2)</td><td align="left" rowspan="1" colspan="1">
<bold>0.002</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">3'-Hydroxycotinine (ng/mL)&#x000a0;</td><td align="left" rowspan="1" colspan="1">99.6 (94.6&#x02013;104.7)</td><td align="left" rowspan="1" colspan="1">91.9 (86.0&#x02013;97.9)</td><td align="left" rowspan="1" colspan="1">88.5 (75.2&#x02013;101.9)</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Sum of Cotinine and 3'-Hydroxycotinine (ng/mL)</td><td align="left" rowspan="1" colspan="1">346.0 (333.1&#x02013;358.9)</td><td align="left" rowspan="1" colspan="1">323.8 (309.5&#x02013;338.2)</td><td align="left" rowspan="1" colspan="1">288.8 (254.7&#x02013;322.9)</td><td align="left" rowspan="1" colspan="1">
<bold>0.005</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">FTND</td><td align="left" rowspan="1" colspan="1">5.4 (5.2&#x02013;5.5)</td><td align="left" rowspan="1" colspan="1">5.3 (5.1&#x02013;5.4)</td><td align="left" rowspan="1" colspan="1">5.4 (4.8&#x02013;6.0)</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">NMR</td><td align="left" rowspan="1" colspan="1">0.42 (0.40&#x02013;0.43)</td><td align="left" rowspan="1" colspan="1">0.40 (0.39&#x02013;0.43)</td><td align="left" rowspan="1" colspan="1">0.46 (0.40&#x02013;0.52)</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (% Female)</td><td align="left" rowspan="1" colspan="1">44%</td><td align="left" rowspan="1" colspan="1">42%</td><td align="left" rowspan="1" colspan="1">38%</td><td align="left" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (Years)</td><td align="left" rowspan="1" colspan="1">45.0 (44.1&#x02013;46.0)</td><td align="left" rowspan="1" colspan="1">47.1 (46.1&#x02013;48.2)</td><td align="left" rowspan="1" colspan="1">47.3 (44.4&#x02013;50.2)</td><td align="left" rowspan="1" colspan="1">
<bold>0.01</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (Kg/m2)</td><td align="left" rowspan="1" colspan="1">28.8 (28.2&#x02013;29.2)</td><td align="left" rowspan="1" colspan="1">29.0 (28.5&#x02013;29.6)</td><td align="left" rowspan="1" colspan="1">28.1 (26.8&#x02013;29.5)</td><td align="left" rowspan="1" colspan="1">0.51</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>
<sup>a</sup> RS16969968: there were 250, 320 and 84 intent-to-treat smokers in the GG, GA and AA group respectively.</p></fn><fn id="t001fn002"><p>
<sup>b</sup> RS588765: there were 219, 325, 110 intent-to-treat smokers in the CC, CT and TT group respectively.</p></fn><fn id="t001fn003"><p>
<sup>c</sup> RS578776: there were 359, 260, 35 intent-to-treat smokers in the GG, GA and AA group respectively.</p></fn><fn id="t001fn004"><p>NMR = nicotine metabolite ratio. FTND = Fagerstrom Test for Nicotine Dependence.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec011"><title>Association between <italic>CHRNA5-A3-B4</italic> genetic variants and cigarettes consumption</title><sec id="sec012"><title>rs16969968</title><p>Among the screened participants, the &#x02018;A&#x02019; allele of rs16969968 was significantly associated with 10% higher cotinine levels (per allele effect = 23.9 ng/mL, CI = 14.4&#x02013;33.4, <italic>P</italic>&#x0003c;0.0001, <xref rid="pone.0128109.g001" ref-type="fig">Fig 1A</xref>), but not significantly with self-reported cigarettes per day (<italic>P</italic> = 0.30, <xref rid="pone.0128109.t001" ref-type="table">Table 1</xref> and <xref rid="pone.0128109.g001" ref-type="fig">Fig 1B</xref>). A significant association between rs16969968 and cotinine was also observed in the intent-to-treat participants (per allele effect = 22.4 ng/mL, CI = 6.7&#x02013;38.1, <italic>P</italic> = 0.005). Interestingly, adjusting for self-reported cigarette consumption very modestly reduced the per allele effect of rs16969968 on cotinine (the per allele effect size of rs16969968 on cotinine was 21.8, CI = 12.6&#x02013;30.9, P&#x0003c;0.0001 after adjusting for cigarettes per day versus the 23.9 ng/mL without adjustment, <xref rid="pone.0128109.g001" ref-type="fig">Fig 1C</xref>), indicating the weakness of self-reported consumption relative to cotinine as a measure of consumption. This suggests that smokers with the &#x02018;A&#x02019; allele of rs16969968 likely extracted more nicotine per cigarette, which is supported by the observation that smokers with the &#x02018;A&#x02019; allele of rs16969968 had significantly higher cotinine per cigarette (<italic>P</italic> = 0.002, <xref rid="pone.0128109.g001" ref-type="fig">Fig 1C</xref>). The association between rs16969968 and smoking behaviors did not differ significantly by gender (data not shown) as previously observed [<xref rid="pone.0128109.ref004" ref-type="bibr">4</xref>&#x02013;<xref rid="pone.0128109.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0128109.ref041" ref-type="bibr">41</xref>].</p><fig id="pone.0128109.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128109.g001</object-id><label>Fig 1</label><caption><title>The association between <italic>CHRNA5-A3-B4</italic> variant rs16969968 and smoking behaviors among Caucasian smokers.</title><p>(a) The &#x02018;A&#x02019; allele of rs16969968 was significantly associated with higher cotinine levels (10.2% higher for GA and 22.5% higher for AA compared to GG). (b) No association between rs16969968 with cigarettes per day was observed. (c) The &#x02018;A&#x02019; allele of rs16969968 was associated with significantly higher smoking intensity as indicated by cotinine per cigarette (6.0% higher for GA and 17.1% higher for AA compared to GG). Kruskal&#x02013;Wallis tests were used for statistical comparisons. GG, GA, &#x00026; AA represent different genotypes of rs16969968.</p></caption><graphic xlink:href="pone.0128109.g001"/></fig></sec><sec id="sec013"><title>rs588765</title><p>Among the screened participants, rs588765 was not significantly associated with cigarettes per day, cotinine levels, or cotinine per cigarette (<xref rid="pone.0128109.t001" ref-type="table">Table 1</xref> and <xref rid="pone.0128109.s001" ref-type="supplementary-material">S1 Fig</xref>). Adjusting for rs16969968 did not significantly alter the association between rs588765 and smoking phenotypes (data not shown).</p></sec><sec id="sec014"><title>rs578776</title><p>Among the screened participants, the &#x02018;A&#x02019; allele of rs578776 was significantly associated with 8% lower cotinine levels (per allele effect is -18.9 ng/mL CI = -29.7 &#x02013;-8.2, <italic>P</italic> = 0.002, <xref rid="pone.0128109.t001" ref-type="table">Table 1</xref> and <xref rid="pone.0128109.s002" ref-type="supplementary-material">S2 Fig</xref>), but not significantly associated with cigarettes per day (<italic>P</italic> = 0.53, <xref rid="pone.0128109.t001" ref-type="table">Table 1</xref> and <xref rid="pone.0128109.s002" ref-type="supplementary-material">S2 Fig</xref>). Adjusting for self-reported cigarette consumption did not substantially reduce the per allele effect size of rs578776 on cotinine levels (the per allele effect size of rs578776 was -18.4 ng/mL, CI = -28.8 &#x02013;-8.1, <italic>P</italic>&#x0003c;0.0001 versus the -18.9 ng/mL without adjustment, <xref rid="pone.0128109.s002" ref-type="supplementary-material">S2 Fig</xref>). However, the association was no longer significant after adjusting for rs16969968 (the per allele effect size was -8.2 ng/mL, CI = -20.24&#x02013;3.93, <italic>P</italic> = 0.19 versus the -18.9 ng/mL without adjustment).</p></sec><sec id="sec015"><title>Haplotype analyses</title><p>Among the screened participants, cigarettes per day and FTND levels did not significantly differ between the <italic>CHRNA5-A3-B4</italic> haplotypes (<xref rid="pone.0128109.t002" ref-type="table">Table 2</xref>). However, haplotype 3 was significantly associated with lower cotinine levels compared to haplotype 1 (<xref rid="pone.0128109.t002" ref-type="table">Table 2</xref>, P&#x0003c;0.0001).</p><table-wrap id="pone.0128109.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128109.t002</object-id><label>Table 2</label><caption><title>The association between <italic>CHRNA5-A3-B4</italic> rs16969968_rs588765 haplotype and baseline smoking behaviors in the screened population (N = 1026).</title></caption><alternatives><graphic id="pone.0128109.t002g" xlink:href="pone.0128109.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">&#x003b2;</th><th align="left" rowspan="1" colspan="1">95% CI</th><th align="left" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td colspan="4" align="center" rowspan="1">
<bold>CIGARETTES PER DAY</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CHRNA5-A3-B4</italic> Haplotype</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 1 (G_C)</td><td colspan="3" align="center" rowspan="1"> Reference</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 2 (G_T)</td><td align="left" rowspan="1" colspan="1">0.32</td><td align="left" rowspan="1" colspan="1">-0.60, 1.25</td><td align="char" char="." rowspan="1" colspan="1">0.492</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 3 (A_C)</td><td align="left" rowspan="1" colspan="1">0.85</td><td align="left" rowspan="1" colspan="1">-0.07, 1.77</td><td align="char" char="." rowspan="1" colspan="1">0.069</td></tr><tr><td align="left" rowspan="1" colspan="1">NMR (&#x0003c;0.31 vs. &#x02265;0.31)</td><td align="left" rowspan="1" colspan="1">1.64</td><td align="left" rowspan="1" colspan="1">0.62, 2.65</td><td align="char" char="." rowspan="1" colspan="1">
<bold>0.001</bold>
</td></tr><tr><td colspan="4" align="center" rowspan="1">
<bold>CO LEVELS</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CHRNA5-A3-B4</italic> Haplotype</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 1 (G_C)</td><td colspan="3" align="center" rowspan="1">Reference</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 2 (G_T)</td><td align="left" rowspan="1" colspan="1">0.23</td><td align="left" rowspan="1" colspan="1">-1.39, 1.86</td><td align="char" char="." rowspan="1" colspan="1">0.776</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 3 (A_C)</td><td align="left" rowspan="1" colspan="1">1.36</td><td align="left" rowspan="1" colspan="1">-0.30, 3.03</td><td align="char" char="." rowspan="1" colspan="1">0.109</td></tr><tr><td align="left" rowspan="1" colspan="1">NMR (&#x0003c;0.31 vs. &#x02265;0.31)</td><td align="left" rowspan="1" colspan="1">1.71</td><td align="left" rowspan="1" colspan="1">0.02, 3.40</td><td align="char" char="." rowspan="1" colspan="1">0.048</td></tr><tr><td colspan="4" align="center" rowspan="1">
<bold>FTND</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CHRNA5-A3-B4</italic> Haplotype</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 1 (G_C)</td><td colspan="3" align="center" rowspan="1">Reference</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 2 (G_T)</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">-0.11, 0.37</td><td align="char" char="." rowspan="1" colspan="1">0.299</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 3 (A_C)</td><td align="left" rowspan="1" colspan="1">0.23</td><td align="left" rowspan="1" colspan="1">-0.079, 0.47</td><td align="char" char="." rowspan="1" colspan="1">0.058</td></tr><tr><td align="left" rowspan="1" colspan="1">NMR (&#x0003c;0.31 vs. &#x02265;0.31)</td><td align="left" rowspan="1" colspan="1">0.26</td><td align="left" rowspan="1" colspan="1">-0.072, 0.52</td><td align="char" char="." rowspan="1" colspan="1">0.057</td></tr><tr><td colspan="4" align="center" rowspan="1">
<bold>Cotinine <xref rid="t002fn003" ref-type="table-fn">*</xref></bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>CHRNA5-A3-B4</italic> Haplotype</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 1 (G_C)</td><td colspan="3" align="center" rowspan="1">Reference</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 2 (G_T)</td><td align="left" rowspan="1" colspan="1">12.2</td><td align="left" rowspan="1" colspan="1">-0.39, 24.8</td><td align="char" char="." rowspan="1" colspan="1">0.058</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 3 (A_C)</td><td align="left" rowspan="1" colspan="1">33.1</td><td align="left" rowspan="1" colspan="1">20.5, 45.7</td><td align="char" char="." rowspan="1" colspan="1">
<bold>&#x0003c;0.001</bold>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>All models were adjusted for age and gender. NMR = nicotine metabolite ratio.</p></fn><fn id="t002fn002"><p>The <italic>CHRNA5-A3-B4</italic> haplotype was defined by rs16969968 and rs588765.</p></fn><fn id="t002fn003"><p>* Cotinine is a part of NMR, and cotinine levels are not directly comparable in people with different NMR [<xref rid="pone.0128109.ref048" ref-type="bibr">48</xref>], thus NMR was not included in the cotinine analysis.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="sec016"><title>Association between <italic>CHRNA5-A3-B4</italic> SNPs and haplotype with smoking cessation</title><p>We next investigated the association between <italic>CHRNA5-A3-B4</italic> variants and smoking abstinence in the intent-to-treat group (N = 654). Overall at EOT, 19.8% of the participants (42 out of 212) receiving the placebo treatment were abstinent, 24.8% of the participants (55 out of 222) receiving the nicotine patch treatment were abstinent, and 38.6% of the participants (85 out of 220) receiving the varenicline treatment were abstinent.</p><sec id="sec017"><title>rs16969968</title><p>Smoking abstinence rates by rs16969968 genotype are shown in <xref rid="pone.0128109.g002" ref-type="fig">Fig 2</xref>. rs16969968 was not significantly associated with smoking abstinence in the total (adjusting for treatment arm), placebo, nicotine patch, or varenicline groups (total odds ratio (OR) = 1.00, 95% CI = 0.70&#x02013;1.42 and P = 0.99, placebo OR = 0.66, 95% CI = 0.33&#x02013;1.31 and P = 0.23, patch OR = 1.01, 95% CI = 0.54&#x02013;1.88 and P = 0.99, or varenicline OR = 1.30, 95% CI = 0.74&#x02013;2.28 and P = 0.36). There were no significant two-way genotype-by-treatment interactions (<xref rid="pone.0128109.s004" ref-type="supplementary-material">S1 Table</xref>). These results were not altered substantially when adjusting for the rate of nicotine metabolism (dichotomized as NMR&#x0003c;0.31 and &#x02265; 0.31 [<xref rid="pone.0128109.ref018" ref-type="bibr">18</xref>]), age, sex, and baseline cigarette consumption (<xref rid="pone.0128109.g002" ref-type="fig">Fig 2</xref>).</p><fig id="pone.0128109.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128109.g002</object-id><label>Fig 2</label><caption><title>The association between rs16969968 and smoking abstinence in Caucasian smokers.</title><p>(a) Rs16969968 was not associated with smoking abstinence in smokers treated with placebo. Adjusting for NMR, sex and age did not significantly alter the association (OR<sub>adjusted</sub> = 0.66, P<sub>adjusted</sub> = 0.24). (b) Rs16969968 was not associated with smoking abstinence in smokers treated with nicotine replacement patch. Adjusting for NMR, sex and age did not significantly alter the association (OR<sub>adjusted</sub> = 0.99, P<sub>adjusted</sub> = 0.98). (c) Rs16969968 was not associated with smoking abstinence in smokers treated with varenicline. Adjusting for NMR, sex and age did not significantly alter the association (OR<sub>adjusted</sub> = 1.29, P<sub>adjusted</sub> = 0.38). The black lines represent the average abstinence rate between the GA and AA group. Statistical significance was evaluated using dominant models (i.e. GG = 0 and GA/AA = 1). OR = odds ratio. NMR = nicotine metabolite ratio. GG, GA, &#x00026; AA represent different genotypes of rs16969968.</p></caption><graphic xlink:href="pone.0128109.g002"/></fig></sec><sec id="sec018"><title>rs588765</title><p>Smoking abstinence rates by rs588765 genotype are shown in <xref rid="pone.0128109.g003" ref-type="fig">Fig 3</xref>. rs588765 was not significantly associated with smoking abstinence in the total (adjusting for treatment arm), placebo, nicotine patch group, or varenicline groups (total OR = 0.82, 95% CI = 0.57&#x02013;1.18 and P = 0.29, placebo OR = 0.96, 95% CI = 0.46&#x02013;1.99 and P = 0.90, patch OR = 0.84, 95% CI = 0.44&#x02013;1.58 and P = 0.58, and varenicline OR = 0.74 95% CI = 0.42&#x02013;1.29 P = 0.29). There were no significant two-way genotype-by-treatment interactions (<xref rid="pone.0128109.s005" ref-type="supplementary-material">S2 Table</xref>). These results were not altered substantially when adjusted for the rate of nicotine metabolism, age, sex, and cigarette consumption (<xref rid="pone.0128109.g003" ref-type="fig">Fig 3</xref>).</p><fig id="pone.0128109.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128109.g003</object-id><label>Fig 3</label><caption><title>The association between rs588765 and smoking abstinence in Caucasian smokers.</title><p>(a) Rs588765 was not associated with smoking abstinence in smokers treated with placebo. Adjusting for NMR, sex and age did not significantly alter the association (OR<sub>adjusted</sub> = 0.97, P<sub>adjusted</sub> = 0.93). (b) Rs588765 was not associated with smoking abstinence in smokers treated with nicotine replacement patch. Adjusting for NMR, sex and age did not significantly alter the association (OR<sub>adjusted</sub> = 0.81, P<sub>adjusted</sub> = 0.52). (c) Rs588765 was not associated with smoking abstinence in smokers treated with varenicline. Adjusting for NMR, sex and age did not significantly alter the association (OR<sub>adjusted</sub> = 0.77, P<sub>adjusted</sub> = 0.36). The black lines represent the average abstinence rate between the CT and TT group. Statistical significance was evaluated using dominant models (i.e. CC = 0 and CT/TT = 1). OR = odds ratio. CC, CT, &#x00026; TT represent different genotypes of rs588765.</p></caption><graphic xlink:href="pone.0128109.g003"/></fig></sec><sec id="sec019"><title>rs578776</title><p>Smoking abstinence rates by rs578776 genotype are shown in <xref rid="pone.0128109.g004" ref-type="fig">Fig 4</xref>. rs578776 was not significantly associated with smoking abstinence in the total (adjusting for treatment arm), placebo, nicotine patch, or varenicline groups (total OR = 0.98, 95% CI = 0.69&#x02013;1.40 and P = 0.93, placebo OR = 1.02, 95% CI = 0.52&#x02013;2.02 and P = 0.95, patch OR = 0.75, 95% CI = 0.40&#x02013;1.38 and P = 0.35, and varenicline OR = 1.20, 95% CI = 0.70&#x02013;2.07 and P = 0.51). There were no significant genotype-by-treatment interactions (<xref rid="pone.0128109.s006" ref-type="supplementary-material">S3 Table</xref>). These results were not altered substantially when adjusted for the rate of nicotine metabolism, age, sex, and cigarette consumption (<xref rid="pone.0128109.g004" ref-type="fig">Fig 4</xref>).</p><fig id="pone.0128109.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128109.g004</object-id><label>Fig 4</label><caption><title>The association between rs578776 and smoking abstinence in Caucasian smokers.</title><p>(a) Rs578776 was not associated with smoking abstinence in smokers treated with placebo. Adjusting for NMR, sex and age did not significantly alter the association (OR<sub>adjusted</sub> = 1.00, P<sub>adjusted</sub> = 0.99). (b) Rs578776 was not associated with smoking abstinence in smokers treated with nicotine replacement patch. Adjusting for NMR, sex and age did not significantly alter the association (OR<sub>adjusted</sub> = 0.74, P<sub>adjusted</sub> = 0.35). (c) Rs578776 was not associated with smoking abstinence in smokers treated with varenicline. Adjusting for NMR, sex and age did not significantly alter the association (OR<sub>adjusted</sub> = 1.14, P<sub>adjusted</sub> = 0.63). The black lines represent the average abstinence rate between the GA and AA group. Statistical significance was evaluated using dominant models (i.e. GG = 0 and GA/AA = 1). OR = odds ratio. NMR = nicotine metabolite ratio. GG, GA, &#x00026; AA represent different genotypes of rs578776.</p></caption><graphic xlink:href="pone.0128109.g004"/></fig></sec><sec id="sec020"><title>Haplotype analyses</title><p>Smoking abstinence rates by rs16969968_rs588765 haplotype are shown in <xref rid="pone.0128109.g005" ref-type="fig">Fig 5</xref>. In logistic regression models, haplotype 2 (G_T) and haplotype 3 (G_C) were not significantly associated with smoking abstinence within each treatment group independently compared to the reference haplotype 1 group (G_C) (OR = 0.74&#x02013;1.16, P&#x0003e;0.05). Furthermore, the haplotypes did not predict abstinence in the entire study group, and no significant haplotype-by-treatment interactions were observed (<xref rid="pone.0128109.t003" ref-type="table">Table 3</xref> and <xref rid="pone.0128109.s003" ref-type="supplementary-material">S3 Fig</xref>.).</p><fig id="pone.0128109.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128109.g005</object-id><label>Fig 5</label><caption><title>The association between <italic>CHRNA5-A3-B4</italic> haplotype and smoking abstinence.</title><p>(a) <italic>CHRNA5-A3-B4</italic> haplotype was not associated with smoking abstinence in smokers treated with placebo. Adjusting for NMR, sex and age did not significantly alter the association (Haplotype 2: OR<sub>adjusted</sub> = 1.21, P<sub>adjusted</sub> = 0.58; Haplotype 3: OR<sub>adjusted</sub> = 1.02, P<sub>adjusted</sub> = 0.96). (b) <italic>CHRNA5-A3-B4</italic> haplotype was not associated with smoking abstinence in smokers treated with nicotine replacement patch. Adjusting for NMR, sex and age did not significantly alter the association (Haplotype 2: OR<sub>adjusted</sub> = 1.06, P<sub>adjusted</sub> = 0.85; Haplotype 3: OR<sub>adjusted</sub> = 1.09, P<sub>adjusted</sub> = 0.78). (c) <italic>CHRNA5-A3-B4</italic> haplotype was not associated with smoking abstinence in smokers treated with varenicline. Adjusting for NMR, sex and age did not significantly alter the association (Haplotype 2: OR<sub>adjusted</sub> = 0.78, P<sub>adjusted</sub> = 0.34; Haplotype 3: OR<sub>adjusted</sub> = 0.98, P<sub>adjusted</sub> = 0.93). The <italic>CHRNA5-A3-B4</italic> haplotype was defined by rs16969968 and rs588765. OR = odds ratio. NMR = nicotine metabolite ratio.</p></caption><graphic xlink:href="pone.0128109.g005"/></fig><table-wrap id="pone.0128109.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128109.t003</object-id><label>Table 3</label><caption><title>The association between <italic>CHRNA5-A3-B4</italic> Haplotype and end of treatment smoking abstinence in the intent to treat population (N = 654).</title></caption><alternatives><graphic id="pone.0128109.t003g" xlink:href="pone.0128109.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th colspan="3" align="center" rowspan="1">Effect on Abstinence at End of Treatment</th></tr><tr><th align="left" rowspan="1" colspan="1">PREDICTORS</th><th align="left" rowspan="1" colspan="1">Odds Ratio</th><th align="left" rowspan="1" colspan="1">95% CI</th><th align="left" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>Haplotype</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 1 (G_C)</td><td colspan="3" align="center" rowspan="1">Reference</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 2 (G_T)</td><td align="left" rowspan="1" colspan="1">0. 98</td><td align="left" rowspan="1" colspan="1">0.46, 2.1</td><td align="char" char="." rowspan="1" colspan="1">0.964</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 3 (A_C)</td><td align="left" rowspan="1" colspan="1">1.15</td><td align="left" rowspan="1" colspan="1">0.60, 2.2</td><td align="char" char="." rowspan="1" colspan="1">0.679</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Treatment</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Placebo</td><td colspan="3" align="center" rowspan="1">Reference</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Active Treatment</td><td align="left" rowspan="1" colspan="1">2.4</td><td align="left" rowspan="1" colspan="1">0.70, 8.23</td><td align="char" char="." rowspan="1" colspan="1">0.165</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Interaction of haplotype and treatment</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 1 and active treatment</td><td colspan="3" align="center" rowspan="1">Reference</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 2 and active treatment</td><td align="left" rowspan="1" colspan="1">1.01</td><td align="left" rowspan="1" colspan="1">0.43, 2.36</td><td align="char" char="." rowspan="1" colspan="1">0.985</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haplotype 3 and active treatment</td><td align="left" rowspan="1" colspan="1">0.75</td><td align="left" rowspan="1" colspan="1">0.35, 1.60</td><td align="char" char="." rowspan="1" colspan="1">0.457</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>All models were adjusted for age, gender and nicotine metabolism.</p></fn><fn id="t003fn002"><p>The <italic>CHRNA5-A3-B4</italic> haplotype was defined by rs16969968 and rs588765 as previously defined [<xref rid="pone.0128109.ref030" ref-type="bibr">30</xref>].</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec021"><title>6 month and 12 month smoking abstinence</title><p>
<italic>CHRNA5-A3-B4</italic> variants rs16969968, rs588765, &#x00026; rs578776 were not significantly associated with smoking abstinence at 6 month and 12 month follow-up (ORs range from 0.54 to 1.98, P values range from 0.11 to 0.92, <xref rid="pone.0128109.s007" ref-type="supplementary-material">S4 Table</xref>). Similarly, rs16969968_rs588765 haplotypes were not significantly associated with smoking abstinence at 6 month and 12 month follow-up (<xref rid="pone.0128109.s008" ref-type="supplementary-material">S5</xref> and <xref rid="pone.0128109.s009" ref-type="supplementary-material">S6</xref> Tables).</p></sec></sec></sec><sec sec-type="conclusions" id="sec022"><title>Discussion</title><p>In this study, we report a lack of association between <italic>CHRNA5-A3-B4</italic> genetic variants/haplotype and end of treatment smoking cessation outcomes in Caucasian smokers despite the expected significant association between <italic>CHRNA5-A3-B4</italic> genetic variants and baseline smoking behaviors (cotinine levels). Our study is the first placebo-controlled clinical trial investigating the association of <italic>CHRNA5-A3-B4</italic> genetic variants with smoking cessation during treatment with the nicotine patch versus varenicline. We observed no significant <italic>CHRNA5-A3-B4</italic> genotype-by-treatment interactions with or without adjusting for the rate of nicotine metabolism (i.e. CYP2A6 activity). Together, these findings would not support the use of <italic>CHRNA5-A3-B4</italic> genetic variants to optimize smoking cessation pharmacotherapy selection in Caucasian smokers. Our findings are in agreement with previous large genome-wide association studies which reported that <italic>CHRNA5-A3-B4</italic> variants on chromosome 15 are associated with tobacco consumption among smokers but not smoking status (i.e., current smoker vs. former smoker, n = 41,278), indicating <italic>CHRNA5-A3-B4</italic> variants are not associated with smoking cessation [<xref rid="pone.0128109.ref005" ref-type="bibr">5</xref>]. Our findings also agree with the conclusions of the Munaf&#x000f2; and colleagues study, which suggested the clinical significance of <italic>CHRNA5-A3-B4</italic> genetic variants on smoking cessation was limited [<xref rid="pone.0128109.ref021" ref-type="bibr">21</xref>].</p><p>On the other hand, our findings are in contrast to those findings reported by Chen and colleagues and Bergen and colleagues, who reported significant associations between <italic>CHRNA5-A3-B4</italic> haplotype and smoking cessation in smokers who received placebo treatment [<xref rid="pone.0128109.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0128109.ref031" ref-type="bibr">31</xref>]. It is worth noting that both of these previous studies were partial secondary analyses of an overlapping clinical trial sample, which had significant heterogeneity in the active treatment group (they had 5 distinct active treatments) and Chen et al., had a relatively small placebo group (n = 132) in contrast to n = 212 in the current study [<xref rid="pone.0128109.ref018" ref-type="bibr">18</xref>]. However, since the <italic>CHRNA5-A3-B4</italic> associations with smoking cessation were primarily observed in their placebo group, it is unclear why the findings differed between our study and these past studies. The current lack of association between <italic>CHRNA5-A3-B4</italic> and smoking cessation was not influenced by the rate of nicotine metabolism (i.e. adjusting for NMR) and a follow-up study by Chen and colleagues reported that <italic>CHRNA5-A3-B4</italic> and <italic>CYP2A6</italic> genotype estimated rate of nicotine metabolism were independent signals [<xref rid="pone.0128109.ref037" ref-type="bibr">37</xref>]. Together this suggests that it is unlikely that the lack of association between <italic>CHRNA5-A3-B4</italic> and smoking cessation observed in the current study is related to differences in nicotine metabolism.</p><p>Smoking cessation is an important and complex smoking phenotype; genetic factors are one of many factors which can influence smoking cessation. One possibility for the discrepancy is the variability in participant demographics across studies. The clinical trial reported in past studies consisted of 58% females, whereas our study had 42% females. All studies followed available guidelines for pharmacotherapy administration. However, it is possible that the content or intensity of behavioral counseling differed across studies. If such contextual factors could alter genetic association results, then it could be argued that the genetic findings are unlikely to be sufficiently robust for use in clinical practice.</p><p>To demonstrate potential clinical utility in treatment decision-making, a significant gene-by-treatment interaction is important; however, we did not observe any evidence or trends in this regard. Recently we have reported that varenicline is more efficacious than nicotine patch in smokers with a faster rate of nicotine metabolism in contrast to smokers with a slower rate of nicotine metabolism [<xref rid="pone.0128109.ref018" ref-type="bibr">18</xref>]. Hence, the rate of nicotine metabolism can be used to predict the most efficacious type of smoking cessation therapy. In the case of <italic>CHRNA5-A3-B4</italic> variants, the existing literature is conflicting, lacking a consistent genotype-by-treatment interaction [<xref rid="pone.0128109.ref019" ref-type="bibr">19</xref>&#x02013;<xref rid="pone.0128109.ref021" ref-type="bibr">21</xref>, <xref rid="pone.0128109.ref030" ref-type="bibr">30</xref>, <xref rid="pone.0128109.ref031" ref-type="bibr">31</xref>]. Therefore, it is unlikely that <italic>CHRNA5-A3-B4</italic> can be used clinically to predict the most effective smoking cessation pharmacotherapy.</p><p>Our conclusions should be interpreted in the context of statistical power. However, in the model of cessation in the full sample of 654 individuals adjusting for treatment arm, the ORs for the <italic>CHRNA5-A3-B4</italic> variants differed very little from 1, suggesting no trends for association. For a treatment arm specific effect, at the current samples size (n = 212 to 222 per arm), we are at 0.8 power to detect any effect size larger than OR = ~2.3 for any genetic variants with a 40% allele frequency. Therefore, our data can statistically support that <italic>CHRNA5-A3-B4</italic> variants do not have a large impact on smoking cessation. Although it is possible that our study was not sufficiently powered to reject a weak association between <italic>CHRNA5-A3-B4</italic> variants and smoking cessation, the absence of clinically meaningful trends in our study and the lack of genotype-by-treatment interactions reported by previous studies would still support our conclusion.</p><p>In contrast to the inconsistent reports on associations with cessation, gene variants in <italic>CHRNA5-A3-B4</italic>, particularly rs16969968 and correlated SNPs, have been consistently associated with tobacco consumption in Caucasian smokers [<xref rid="pone.0128109.ref004" ref-type="bibr">4</xref>&#x02013;<xref rid="pone.0128109.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0128109.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0128109.ref012" ref-type="bibr">12</xref>]. In this study, we observed a significant association between rs16969968 and cotinine levels. The &#x02018;A&#x02019; allele of rs16969968 was associated with a roughly 23.9 ng/ml increase in cotinine per allele. These effect sizes were within the previously reported range of 24&#x02013;100 ng/ml per allele [<xref rid="pone.0128109.ref042" ref-type="bibr">42</xref>&#x02013;<xref rid="pone.0128109.ref044" ref-type="bibr">44</xref>]. In contrast, we did not observe any significant association between <italic>CHRNA5-A3-B4</italic> variants and cigarettes per day despite the significant association between nicotine metabolism rate and cigarettes per day. A number of previous studies have also found that the rate of nicotine metabolism has a greater influence on cigarette consumption (i.e. cigarettes smoked per day, total nicotine equivalents) compared to <italic>CHRNA5-A3-B4</italic> gene variants [<xref rid="pone.0128109.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0128109.ref045" ref-type="bibr">45</xref>]. Thus, it is interesting that <italic>CHRNA5-A3-B4</italic> variants generally have a greater effect on lung cancer risk than variation in nicotine metabolism [<xref rid="pone.0128109.ref045" ref-type="bibr">45</xref>]. This observation suggests that the <italic>CHRNA5-A3-B4</italic> gene variants may modulate lung cancer risk by mechanisms in addition to their effects on smoking behavior, such as directly altering cell proliferation and survival [<xref rid="pone.0128109.ref046" ref-type="bibr">46</xref>]. This hypothesis could be directly tested by measuring better tobacco consumption biomarkers (such as urinary total nicotine equivalents) in lung cancer epidemiology studies [<xref rid="pone.0128109.ref042" ref-type="bibr">42</xref>, <xref rid="pone.0128109.ref047" ref-type="bibr">47</xref>].</p><p>In conclusion, the findings of our study, in conjunction with some previous reports, demonstrated a lack of <italic>CHRNA5-A3-B4</italic> genotype by active smoking cessation pharmacotherapy interaction in smokers, and no effect within any treatment arm including placebo. Thus these current and previous data together suggest that it is unlikely that <italic>CHRNA5-A3-B4</italic> could be used clinically to predict the most effective smoking cessation pharmacotherapy to offer to the individual smoker seeking to quit.</p></sec><sec sec-type="supplementary-material" id="sec023"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0128109.s001"><label>S1 Fig</label><caption><title>The association between <italic>CHRNA5-A3-B4</italic> variant rs588765 and smoking behaviors among Caucasian smokers.</title><p>(a) No association between rs588765 with cotinine levels was observed. (b) No association between rs588765 with cigarettes per day was observed. (c) No association between rs588765 with smoking intensity (as indicated by cotinine per cigarette) was observed. Kruskal&#x02013;Wallis tests were used for statistical comparisons.</p><p>(DOCX)</p></caption><media xlink:href="pone.0128109.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128109.s002"><label>S2 Fig</label><caption><title>The association between <italic>CHRNA5-A3-B4</italic> variant rs578776 and smoking behaviors among Caucasian smokers.</title><p>(a) The &#x02018;A&#x02019; allele of rs578776 was associated with significantly lower cotinine levels. (b) No association between rs578776 with cigarettes per day was observed. (c) The &#x02018;A&#x02019; allele of rs578776 was associated with significantly lower smoking intensity as indicated by cotinine per cigarette. Kruskal&#x02013;Wallis tests were used for statistical comparisons.</p><p>(DOCX)</p></caption><media xlink:href="pone.0128109.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128109.s003"><label>S3 Fig</label><caption><title>The association between <italic>CHRNA5-A3-B4</italic> haplotype rs16969968_rs588765 and smoking abstinence at end of treatment.</title><p>(DOCX)</p></caption><media xlink:href="pone.0128109.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128109.s004"><label>S1 Table</label><caption><title>The two-way interaction table for rs16969968 on smoking cessation.</title><p>(DOCX)</p></caption><media xlink:href="pone.0128109.s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128109.s005"><label>S2 Table</label><caption><title>The two-way interaction table for rs588765 on smoking cessation.</title><p>(DOCX)</p></caption><media xlink:href="pone.0128109.s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128109.s006"><label>S3 Table</label><caption><title>The two way interaction table for rs578776 on smoking cessation.</title><p>(DOCX)</p></caption><media xlink:href="pone.0128109.s006.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128109.s007"><label>S4 Table</label><caption><title>The association between <italic>CHRNA5-A3-B4</italic> variants and 6 month and 12 month smoking abstinence in the intent to treat population (N = 654)</title><p>(DOCX)</p></caption><media xlink:href="pone.0128109.s007.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128109.s008"><label>S5 Table</label><caption><title>The association between <italic>CHRNA5-A3-B4</italic> Haplotype and 6 month smoking abstinence in the intent to treat population (N = 654).</title><p>(DOCX)</p></caption><media xlink:href="pone.0128109.s008.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128109.s009"><label>S6 Table</label><caption><title>The association between <italic>CHRNA5-A3-B4</italic> Haplotype and 12 month smoking abstinence in the intent to treat population (N = 654).</title><p>(DOCX)</p></caption><media xlink:href="pone.0128109.s009.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>This work was supported by a grant from the National Institute on Drug Abuse, the National Cancer Institute, the National Human Genome Research Institute, and the National Institute on General Medical Sciences (U01 DA20830; CL and RFT), funding from the Abramson Cancer Center at the University of Pennsylvania (P30 CA16520; CL), a grant from the Commonwealth of Pennsylvania Department of Health (CL), a grant from the Canadian Institutes of Health Research (CIHR TMH109787), an endowed Chair in Addiction for the Department of Psychiatry (RFT), CAMH foundation (RFT), the Canada Foundation for Innovation (#20289 and #16014), and the Ontario Ministry of Research and Innovation (RFT). No funder had a role in study design, collection and analysis of data, writing of the manuscript, or in the decision to submit this manuscript for review. We thank Drs. Li-Shiun Chen and Laura Bierut for providing the methodological details regarding the haplotype imputation used in Chen et al., 2012.</p><p>Pharmacogenomics Research Network: Pharmacogenetics of Nicotine Addiction Treatment (PGRN-PNAT) Research Group includes: Frank Leone, Henry Glick, Angela Pinto, Paul Sanborn, Peter Gariti, Richard Landis (University of Pennsylvania); Maria Novalen, Bin Zhao, Ewa Hoffmann, Qian Zhou, Adel Aziziyeh (CAMH/University of Toronto); Martin Mahoney (Roswell Cancer Center, University of Buffalo); Maher Karam-Hage (The University of Texas M.D. Anderson Cancer Center); David Conti (University of Southern California); Andrew Bergen (SRI International).</p></ack><ref-list><title>References</title><ref id="pone.0128109.ref001"><label>1</label><mixed-citation publication-type="other">World Health Organization. Who report on the global tobacco epidemic, 2011: Warning about the dangers of tobacco. 2011.</mixed-citation></ref><ref id="pone.0128109.ref002"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Jha</surname><given-names>P</given-names></name>, <name><surname>Ramasundarahettige</surname><given-names>C</given-names></name>, <name><surname>Landsman</surname><given-names>V</given-names></name>, <name><surname>Rostron</surname><given-names>B</given-names></name>, <name><surname>Thun</surname><given-names>M</given-names></name>, <name><surname>Anderson</surname><given-names>RN</given-names></name>, <etal>et al</etal>
<article-title>21st-century hazards of smoking and benefits of cessation in the United States</article-title>. <source>N Engl J Med</source>. <year>2013</year>;<volume>368</volume>(<issue>4</issue>):<fpage>341</fpage>&#x02013;<lpage>50</lpage>. Epub 2013/01/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMsa1211128">10.1056/NEJMsa1211128</ext-link></comment>
.<pub-id pub-id-type="pmid">23343063</pub-id></mixed-citation></ref><ref id="pone.0128109.ref003"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Benowitz</surname><given-names>NL</given-names></name>. <article-title>Nicotine addiction</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>362</volume>(<issue>24</issue>):<fpage>2295</fpage>&#x02013;<lpage>303</lpage>. Epub 2010/06/18. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMra0809890">10.1056/NEJMra0809890</ext-link></comment>
; PubMed Central PMCID: PMC2928221.<pub-id pub-id-type="pmid">20554984</pub-id></mixed-citation></ref><ref id="pone.0128109.ref004"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Thorgeirsson</surname><given-names>TE</given-names></name>, <name><surname>Geller</surname><given-names>F</given-names></name>, <name><surname>Sulem</surname><given-names>P</given-names></name>, <name><surname>Rafnar</surname><given-names>T</given-names></name>, <name><surname>Wiste</surname><given-names>A</given-names></name>, <name><surname>Magnusson</surname><given-names>KP</given-names></name>, <etal>et al</etal>
<article-title>A variant associated with nicotine dependence, lung cancer and peripheral arterial disease</article-title>. <source>Nature</source>. <year>2008</year>;<volume>452</volume>(<issue>7187</issue>):<fpage>638</fpage>&#x02013;<lpage>42</lpage>. Epub 2008/04/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature06846">10.1038/nature06846</ext-link></comment>
.<pub-id pub-id-type="pmid">18385739</pub-id></mixed-citation></ref><ref id="pone.0128109.ref005"><label>5</label><mixed-citation publication-type="journal">
<collab>Consortium TTaG</collab>. <article-title>Genome-wide meta-analyses identify multiple loci associated with smoking behavior</article-title>. <source>Nature genetics</source>. <year>2010</year>;<volume>42</volume>(<issue>5</issue>):<fpage>441</fpage>&#x02013;<lpage>7</lpage>. Epub 2010/04/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.571">10.1038/ng.571</ext-link></comment>
; PubMed Central PMCID: PMC2914600.<pub-id pub-id-type="pmid">20418890</pub-id></mixed-citation></ref><ref id="pone.0128109.ref006"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Thorgeirsson</surname><given-names>TE</given-names></name>, <name><surname>Gudbjartsson</surname><given-names>DF</given-names></name>, <name><surname>Surakka</surname><given-names>I</given-names></name>, <name><surname>Vink</surname><given-names>JM</given-names></name>, <name><surname>Amin</surname><given-names>N</given-names></name>, <name><surname>Geller</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior</article-title>. <source>Nat Genet</source>. <year>2010</year>;<volume>42</volume>(<issue>5</issue>):<fpage>448</fpage>&#x02013;<lpage>53</lpage>. Epub 2010/04/27. doi: ng.573 [pii] <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.573">10.1038/ng.573</ext-link></comment>
; PubMed Central PMCID: PMC3080600.<pub-id pub-id-type="pmid">20418888</pub-id></mixed-citation></ref><ref id="pone.0128109.ref007"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Liu</surname><given-names>JZ</given-names></name>, <name><surname>Tozzi</surname><given-names>F</given-names></name>, <name><surname>Waterworth</surname><given-names>DM</given-names></name>, <name><surname>Pillai</surname><given-names>SG</given-names></name>, <name><surname>Muglia</surname><given-names>P</given-names></name>, <name><surname>Middleton</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Meta-analysis and imputation refines the association of 15q25 with smoking quantity</article-title>. <source>Nat Genet</source>. <year>2010</year>;<volume>42</volume>(<issue>5</issue>):<fpage>436</fpage>&#x02013;<lpage>40</lpage>. Epub 2010/04/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.572">10.1038/ng.572</ext-link></comment>
.<pub-id pub-id-type="pmid">20418889</pub-id></mixed-citation></ref><ref id="pone.0128109.ref008"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Pillai</surname><given-names>SG</given-names></name>, <name><surname>Ge</surname><given-names>D</given-names></name>, <name><surname>Zhu</surname><given-names>G</given-names></name>, <name><surname>Kong</surname><given-names>X</given-names></name>, <name><surname>Shianna</surname><given-names>KV</given-names></name>, <name><surname>Need</surname><given-names>AC</given-names></name>, <etal>et al</etal>
<article-title>A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci</article-title>. <source>PLoS Genet</source>. <year>2009</year>;<volume>5</volume>(<issue>3</issue>):<fpage>e1000421</fpage> Epub 2009/03/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pgen.1000421">10.1371/journal.pgen.1000421</ext-link></comment>
; PubMed Central PMCID: PMC2650282.<pub-id pub-id-type="pmid">19300482</pub-id></mixed-citation></ref><ref id="pone.0128109.ref009"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Siedlinski</surname><given-names>M</given-names></name>, <name><surname>Cho</surname><given-names>MH</given-names></name>, <name><surname>Bakke</surname><given-names>P</given-names></name>, <name><surname>Gulsvik</surname><given-names>A</given-names></name>, <name><surname>Lomas</surname><given-names>DA</given-names></name>, <name><surname>Anderson</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Genome-wide association study of smoking behaviours in patients with COPD</article-title>. <source>Thorax</source>. <year>2011</year>;<volume>66</volume>(<issue>10</issue>):<fpage>894</fpage>&#x02013;<lpage>902</lpage>. Epub 2011/06/21. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/thoraxjnl-2011-200154">10.1136/thoraxjnl-2011-200154</ext-link></comment>
; PubMed Central PMCID: PMC3302576.<pub-id pub-id-type="pmid">21685187</pub-id></mixed-citation></ref><ref id="pone.0128109.ref010"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Saccone</surname><given-names>SF</given-names></name>, <name><surname>Hinrichs</surname><given-names>AL</given-names></name>, <name><surname>Saccone</surname><given-names>NL</given-names></name>, <name><surname>Chase</surname><given-names>GA</given-names></name>, <name><surname>Konvicka</surname><given-names>K</given-names></name>, <name><surname>Madden</surname><given-names>PA</given-names></name>, <etal>et al</etal>
<article-title>Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs</article-title>. <source>Hum Mol Genet</source>. <year>2007</year>;<volume>16</volume>(<issue>1</issue>):<fpage>36</fpage>&#x02013;<lpage>49</lpage>. Epub 2006/12/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/ddl438">10.1093/hmg/ddl438</ext-link></comment>
; PubMed Central PMCID: PMC2270437.<pub-id pub-id-type="pmid">17135278</pub-id></mixed-citation></ref><ref id="pone.0128109.ref011"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Saccone</surname><given-names>NL</given-names></name>, <name><surname>Schwantes-An</surname><given-names>TH</given-names></name>, <name><surname>Wang</surname><given-names>JC</given-names></name>, <name><surname>Grucza</surname><given-names>RA</given-names></name>, <name><surname>Breslau</surname><given-names>N</given-names></name>, <name><surname>Hatsukami</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Multiple cholinergic nicotinic receptor genes affect nicotine dependence risk in African and European Americans</article-title>. <source>Genes, brain, and behavior</source>. <year>2010</year>;<volume>9</volume>(<issue>7</issue>):<fpage>741</fpage>&#x02013;<lpage>50</lpage>. Epub 2010/06/30. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1601-183X.2010.00608.x">10.1111/j.1601-183X.2010.00608.x</ext-link></comment>
; PubMed Central PMCID: PMC2970751.<pub-id pub-id-type="pmid">20584212</pub-id></mixed-citation></ref><ref id="pone.0128109.ref012"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Saccone</surname><given-names>NL</given-names></name>, <name><surname>Culverhouse</surname><given-names>RC</given-names></name>, <name><surname>Schwantes-An</surname><given-names>TH</given-names></name>, <name><surname>Cannon</surname><given-names>DS</given-names></name>, <name><surname>Chen</surname><given-names>X</given-names></name>, <name><surname>Cichon</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and</article-title>
<source>COPD. PLoS Genet</source>. <year>2010</year>;<volume>6</volume>(<issue>8</issue>). Epub 2010/08/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pgen.1001053">10.1371/journal.pgen.1001053</ext-link></comment>
; PubMed Central PMCID: PMC2916847.<pub-id pub-id-type="pmid">20700436</pub-id></mixed-citation></ref><ref id="pone.0128109.ref013"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Gonzales</surname><given-names>D</given-names></name>, <name><surname>Rennard</surname><given-names>SI</given-names></name>, <name><surname>Nides</surname><given-names>M</given-names></name>, <name><surname>Oncken</surname><given-names>C</given-names></name>, <name><surname>Azoulay</surname><given-names>S</given-names></name>, <name><surname>Billing</surname><given-names>CB</given-names></name>, <etal>et al</etal>
<article-title>Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial</article-title>. <source>JAMA</source>. <year>2006</year>;<volume>296</volume>(<issue>1</issue>):<fpage>47</fpage>&#x02013;<lpage>55</lpage>. Epub 2006/07/06. doi: 296/1/47 [pii]. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.296.1.47">10.1001/jama.296.1.47</ext-link></comment>
.<pub-id pub-id-type="pmid">16820546</pub-id></mixed-citation></ref><ref id="pone.0128109.ref014"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Xian</surname><given-names>H</given-names></name>, <name><surname>Scherrer</surname><given-names>JF</given-names></name>, <name><surname>Madden</surname><given-names>PA</given-names></name>, <name><surname>Lyons</surname><given-names>MJ</given-names></name>, <name><surname>Tsuang</surname><given-names>M</given-names></name>, <name><surname>True</surname><given-names>WR</given-names></name>, <etal>et al</etal>
<article-title>The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit</article-title>. <source>Nicotine Tob Res</source>. <year>2003</year>;<volume>5</volume>(<issue>2</issue>):<fpage>245</fpage>&#x02013;<lpage>54</lpage>. Epub 2003/05/15. .<pub-id pub-id-type="pmid">12745498</pub-id></mixed-citation></ref><ref id="pone.0128109.ref015"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Cahill</surname><given-names>K</given-names></name>, <name><surname>Stevens</surname><given-names>S</given-names></name>, <name><surname>Perera</surname><given-names>R</given-names></name>, <name><surname>Lancaster</surname><given-names>T</given-names></name>. <article-title>Pharmacological interventions for smoking cessation: an overview and network meta-analysis</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2013</year>;<volume>5</volume>:CD009329. Epub 2013/06/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/14651858.CD009329.pub2">10.1002/14651858.CD009329.pub2</ext-link></comment>
.<pub-id pub-id-type="pmid">23728690</pub-id></mixed-citation></ref><ref id="pone.0128109.ref016"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Stead</surname><given-names>LF</given-names></name>, <name><surname>Perera</surname><given-names>R</given-names></name>, <name><surname>Bullen</surname><given-names>C</given-names></name>, <name><surname>Mant</surname><given-names>D</given-names></name>, <name><surname>Hartmann-Boyce</surname><given-names>J</given-names></name>, <name><surname>Cahill</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Nicotine replacement therapy for smoking cessation</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2012</year>;<volume>11</volume>:CD000146. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/14651858.CD000146.pub4">10.1002/14651858.CD000146.pub4</ext-link></comment>
.<pub-id pub-id-type="pmid">23152200</pub-id></mixed-citation></ref><ref id="pone.0128109.ref017"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Lessov</surname><given-names>CN</given-names></name>, <name><surname>Martin</surname><given-names>NG</given-names></name>, <name><surname>Statham</surname><given-names>DJ</given-names></name>, <name><surname>Todorov</surname><given-names>AA</given-names></name>, <name><surname>Slutske</surname><given-names>WS</given-names></name>, <name><surname>Bucholz</surname><given-names>KK</given-names></name>, <etal>et al</etal>
<article-title>Defining nicotine dependence for genetic research: evidence from Australian twins</article-title>. <source>Psychological medicine</source>. <year>2004</year>;<volume>34</volume>(<issue>5</issue>):<fpage>865</fpage>&#x02013;<lpage>79</lpage>. .<pub-id pub-id-type="pmid">15500307</pub-id></mixed-citation></ref><ref id="pone.0128109.ref018"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Lerman</surname><given-names>C</given-names></name>, <name><surname>Schnoll</surname><given-names>RA</given-names></name>, <name><surname>Hawk</surname><given-names>LW</given-names><suffix>Jr.</suffix></name>, <name><surname>Cinciripini</surname><given-names>P</given-names></name>, <name><surname>George</surname><given-names>TP</given-names></name>, <name><surname>Wileyto</surname><given-names>EP</given-names></name>, <etal>et al</etal>
<article-title>Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial</article-title>. <source>The lancet Respiratory medicine</source>. <year>2015</year>;<volume>3</volume>(<issue>2</issue>):<fpage>131</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S2213-2600(14)70294-2">10.1016/S2213-2600(14)70294-2</ext-link></comment>
.<pub-id pub-id-type="pmid">25588294</pub-id></mixed-citation></ref><ref id="pone.0128109.ref019"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Baker</surname><given-names>TB</given-names></name>, <name><surname>Weiss</surname><given-names>RB</given-names></name>, <name><surname>Bolt</surname><given-names>D</given-names></name>, <name><surname>von Niederhausern</surname><given-names>A</given-names></name>, <name><surname>Fiore</surname><given-names>MC</given-names></name>, <name><surname>Dunn</surname><given-names>DM</given-names></name>, <etal>et al</etal>
<article-title>Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes</article-title>. <source>Nicotine Tob Res</source>. <year>2009</year>;<volume>11</volume>(<issue>7</issue>):<fpage>785</fpage>&#x02013;<lpage>96</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ntr/ntp064">10.1093/ntr/ntp064</ext-link></comment>
; PubMed Central PMCID: PMC2699926.<pub-id pub-id-type="pmid">19436041</pub-id></mixed-citation></ref><ref id="pone.0128109.ref020"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Freathy</surname><given-names>RM</given-names></name>, <name><surname>Ring</surname><given-names>SM</given-names></name>, <name><surname>Shields</surname><given-names>B</given-names></name>, <name><surname>Galobardes</surname><given-names>B</given-names></name>, <name><surname>Knight</surname><given-names>B</given-names></name>, <name><surname>Weedon</surname><given-names>MN</given-names></name>, <etal>et al</etal>
<article-title>A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy</article-title>. <source>Hum Mol Genet</source>. <year>2009</year>;<volume>18</volume>(<issue>15</issue>):<fpage>2922</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/ddp216">10.1093/hmg/ddp216</ext-link></comment>
; PubMed Central PMCID: PMC2706684.<pub-id pub-id-type="pmid">19429911</pub-id></mixed-citation></ref><ref id="pone.0128109.ref021"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Munafo</surname><given-names>MR</given-names></name>, <name><surname>Johnstone</surname><given-names>EC</given-names></name>, <name><surname>Walther</surname><given-names>D</given-names></name>, <name><surname>Uhl</surname><given-names>GR</given-names></name>, <name><surname>Murphy</surname><given-names>MF</given-names></name>, <name><surname>Aveyard</surname><given-names>P</given-names></name>. <article-title>CHRNA3 rs1051730 genotype and short-term smoking cessation</article-title>. <source>Nicotine Tob Res</source>. <year>2011</year>;<volume>13</volume>(<issue>10</issue>):<fpage>982</fpage>&#x02013;<lpage>8</lpage>. Epub 2011/06/22. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ntr/ntr106">10.1093/ntr/ntr106</ext-link></comment>
; PubMed Central PMCID: PMC3179672.<pub-id pub-id-type="pmid">21690317</pub-id></mixed-citation></ref><ref id="pone.0128109.ref022"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Sarginson</surname><given-names>JE</given-names></name>, <name><surname>Killen</surname><given-names>JD</given-names></name>, <name><surname>Lazzeroni</surname><given-names>LC</given-names></name>, <name><surname>Fortmann</surname><given-names>SP</given-names></name>, <name><surname>Ryan</surname><given-names>HS</given-names></name>, <name><surname>Schatzberg</surname><given-names>AF</given-names></name>, <etal>et al</etal>
<article-title>Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy</article-title>. <source>Am J Med Genet B Neuropsychiatr Genet</source>. <year>2011</year>;<volume>156B</volume>(<issue>3</issue>):<fpage>275</fpage>&#x02013;<lpage>84</lpage>. Epub 2011/01/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ajmg.b.31155">10.1002/ajmg.b.31155</ext-link></comment>
.<pub-id pub-id-type="pmid">21268243</pub-id></mixed-citation></ref><ref id="pone.0128109.ref023"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Zhu</surname><given-names>AZ</given-names></name>, <name><surname>Zhou</surname><given-names>Q</given-names></name>, <name><surname>Cox</surname><given-names>LS</given-names></name>, <name><surname>David</surname><given-names>SP</given-names></name>, <name><surname>Ahluwalia</surname><given-names>JS</given-names></name>, <name><surname>Benowitz</surname><given-names>NL</given-names></name>, <etal>et al</etal>
<article-title>Association of CHRNA5-A3-B4 SNP rs2036527 With Smoking Cessation Therapy Response in African-American Smokers</article-title>. <source>Clin Pharmacol Ther</source>. <year>2014</year>;<volume>96</volume>(<issue>2</issue>):<fpage>256</fpage>&#x02013;<lpage>65</lpage>. Epub 2014/04/16. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/clpt.2014.88">10.1038/clpt.2014.88</ext-link></comment>
; PubMed Central PMCID: PMC4111775.<pub-id pub-id-type="pmid">24733007</pub-id></mixed-citation></ref><ref id="pone.0128109.ref024"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Breitling</surname><given-names>LP</given-names></name>, <name><surname>Twardella</surname><given-names>D</given-names></name>, <name><surname>Hoffmann</surname><given-names>MM</given-names></name>, <name><surname>Witt</surname><given-names>SH</given-names></name>, <name><surname>Treutlein</surname><given-names>J</given-names></name>, <name><surname>Brenner</surname><given-names>H</given-names></name>. <article-title>Prospective association of dopamine-related polymorphisms with smoking cessation in general care</article-title>. <source>Pharmacogenomics</source>. <year>2010</year>;<volume>11</volume>(<issue>4</issue>):<fpage>527</fpage>&#x02013;<lpage>36</lpage>. Epub 2010/03/31. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2217/pgs.10.1">10.2217/pgs.10.1</ext-link></comment>
.<pub-id pub-id-type="pmid">20350135</pub-id></mixed-citation></ref><ref id="pone.0128109.ref025"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Conti</surname><given-names>DV</given-names></name>, <name><surname>Lee</surname><given-names>W</given-names></name>, <name><surname>Li</surname><given-names>D</given-names></name>, <name><surname>Liu</surname><given-names>J</given-names></name>, <name><surname>Van Den Berg</surname><given-names>D</given-names></name>, <name><surname>Thomas</surname><given-names>PD</given-names></name>, <etal>et al</etal>
<article-title>Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation</article-title>. <source>Hum Mol Genet</source>. <year>2008</year>;<volume>17</volume>(<issue>18</issue>):<fpage>2834</fpage>&#x02013;<lpage>48</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/ddn181">10.1093/hmg/ddn181</ext-link></comment>
; PubMed Central PMCID: PMC2525499.<pub-id pub-id-type="pmid">18593715</pub-id></mixed-citation></ref><ref id="pone.0128109.ref026"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Swan</surname><given-names>GE</given-names></name>, <name><surname>Javitz</surname><given-names>HS</given-names></name>, <name><surname>Jack</surname><given-names>LM</given-names></name>, <name><surname>Wessel</surname><given-names>J</given-names></name>, <name><surname>Michel</surname><given-names>M</given-names></name>, <name><surname>Hinds</surname><given-names>DA</given-names></name>, <etal>et al</etal>
<article-title>Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes</article-title>. <source>Pharmacogenomics J</source>. <year>2012</year>;<volume>12</volume>(<issue>4</issue>):<fpage>349</fpage>&#x02013;<lpage>58</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/tpj.2011.19">10.1038/tpj.2011.19</ext-link></comment>
; PubMed Central PMCID: PMC3405554.<pub-id pub-id-type="pmid">21606948</pub-id></mixed-citation></ref><ref id="pone.0128109.ref027"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Uhl</surname><given-names>GR</given-names></name>, <name><surname>Drgon</surname><given-names>T</given-names></name>, <name><surname>Johnson</surname><given-names>C</given-names></name>, <name><surname>Ramoni</surname><given-names>MF</given-names></name>, <name><surname>Behm</surname><given-names>FM</given-names></name>, <name><surname>Rose</surname><given-names>JE</given-names></name>. <article-title>Genome-wide association for smoking cessation success in a trial of precessation nicotine replacement</article-title>. <source>Mol Med</source>. <year>2010</year>;<volume>16</volume>(<issue>11&#x02013;12</issue>):<fpage>513</fpage>&#x02013;<lpage>26</lpage>. Epub 2010/09/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2119/molmed.2010.00052">10.2119/molmed.2010.00052</ext-link></comment>
; PubMed Central PMCID: PMC2972392.<pub-id pub-id-type="pmid">20811658</pub-id></mixed-citation></ref><ref id="pone.0128109.ref028"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Uhl</surname><given-names>GR</given-names></name>, <name><surname>Liu</surname><given-names>QR</given-names></name>, <name><surname>Drgon</surname><given-names>T</given-names></name>, <name><surname>Johnson</surname><given-names>C</given-names></name>, <name><surname>Walther</surname><given-names>D</given-names></name>, <name><surname>Rose</surname><given-names>JE</given-names></name>. <article-title>Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs</article-title>. <source>BMC genetics</source>. <year>2007</year>;<volume>8</volume>:<fpage>10</fpage> Epub 2007/04/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2156-8-10">10.1186/1471-2156-8-10</ext-link></comment>
; PubMed Central PMCID: PMC1853105.<pub-id pub-id-type="pmid">17407593</pub-id></mixed-citation></ref><ref id="pone.0128109.ref029"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Uhl</surname><given-names>GR</given-names></name>, <name><surname>Liu</surname><given-names>QR</given-names></name>, <name><surname>Drgon</surname><given-names>T</given-names></name>, <name><surname>Johnson</surname><given-names>C</given-names></name>, <name><surname>Walther</surname><given-names>D</given-names></name>, <name><surname>Rose</surname><given-names>JE</given-names></name>, <etal>et al</etal>
<article-title>Molecular genetics of successful smoking cessation: convergent genome-wide association study results</article-title>. <source>Arch Gen Psychiatry</source>. <year>2008</year>;<volume>65</volume>(<issue>6</issue>):<fpage>683</fpage>&#x02013;<lpage>93</lpage>. Epub 2008/06/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/archpsyc.65.6.683">10.1001/archpsyc.65.6.683</ext-link></comment>
; PubMed Central PMCID: PMC2430596.<pub-id pub-id-type="pmid">18519826</pub-id></mixed-citation></ref><ref id="pone.0128109.ref030"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Chen</surname><given-names>LS</given-names></name>, <name><surname>Baker</surname><given-names>TB</given-names></name>, <name><surname>Piper</surname><given-names>ME</given-names></name>, <name><surname>Breslau</surname><given-names>N</given-names></name>, <name><surname>Cannon</surname><given-names>DS</given-names></name>, <name><surname>Doheny</surname><given-names>KF</given-names></name>, <etal>et al</etal>
<article-title>Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success</article-title>. <source>Am J Psychiatry</source>. <year>2012</year>;<volume>169</volume>(<issue>7</issue>):<fpage>735</fpage>&#x02013;<lpage>42</lpage>. Epub 2012/06/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1176/appi.ajp.2012.11101545">10.1176/appi.ajp.2012.11101545</ext-link></comment>
; PubMed Central PMCID: PMC3433845.<pub-id pub-id-type="pmid">22648373</pub-id></mixed-citation></ref><ref id="pone.0128109.ref031"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Bergen</surname><given-names>AW</given-names></name>, <name><surname>Javitz</surname><given-names>HS</given-names></name>, <name><surname>Krasnow</surname><given-names>R</given-names></name>, <name><surname>Nishita</surname><given-names>D</given-names></name>, <name><surname>Michel</surname><given-names>M</given-names></name>, <name><surname>Conti</surname><given-names>DV</given-names></name>, <etal>et al</etal>
<article-title>Nicotinic acetylcholine receptor variation and response to smoking cessation therapies</article-title>. <source>Pharmacogenet Genomics</source>. <year>2013</year>;<volume>23</volume>(<issue>2</issue>):<fpage>94</fpage>&#x02013;<lpage>103</lpage>. Epub 2012/12/20. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/FPC.0b013e32835cdabd">10.1097/FPC.0b013e32835cdabd</ext-link></comment>
; PubMed Central PMCID: PMC3563676.<pub-id pub-id-type="pmid">23249876</pub-id></mixed-citation></ref><ref id="pone.0128109.ref032"><label>32</label><mixed-citation publication-type="journal">
<collab>SRNT Subcommittee on Biochemical Verification</collab>. <article-title>Biochemical verification of tobacco use and cessation</article-title>. <source>Nicotine Tob Res</source>. <year>2002</year>;<volume>4</volume>(<issue>2</issue>):<fpage>149</fpage>&#x02013;<lpage>59</lpage>. Epub 2002/05/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/14622200210123581">10.1080/14622200210123581</ext-link></comment>
.<pub-id pub-id-type="pmid">12028847</pub-id></mixed-citation></ref><ref id="pone.0128109.ref033"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Purcell</surname><given-names>S</given-names></name>, <name><surname>Neale</surname><given-names>B</given-names></name>, <name><surname>Todd-Brown</surname><given-names>K</given-names></name>, <name><surname>Thomas</surname><given-names>L</given-names></name>, <name><surname>Ferreira</surname><given-names>MA</given-names></name>, <name><surname>Bender</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses</article-title>. <source>Am J Hum Genet</source>. <year>2007</year>;<volume>81</volume>(<issue>3</issue>):<fpage>559</fpage>&#x02013;<lpage>75</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/519795">10.1086/519795</ext-link></comment>
; PubMed Central PMCID: PMC1950838.<pub-id pub-id-type="pmid">17701901</pub-id></mixed-citation></ref><ref id="pone.0128109.ref034"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Lea</surname><given-names>RA</given-names></name>, <name><surname>Dickson</surname><given-names>S</given-names></name>, <name><surname>Benowitz</surname><given-names>NL</given-names></name>. <article-title>Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate</article-title>. <source>J Anal Toxicol</source>. <year>2006</year>;<volume>30</volume>(<issue>6</issue>):<fpage>386</fpage>&#x02013;<lpage>9</lpage>. Epub 2006/07/29. .<pub-id pub-id-type="pmid">16872570</pub-id></mixed-citation></ref><ref id="pone.0128109.ref035"><label>35</label><mixed-citation publication-type="journal">
<name><surname>St Helen</surname><given-names>G</given-names></name>, <name><surname>Novalen</surname><given-names>M</given-names></name>, <name><surname>Heitjan</surname><given-names>DF</given-names></name>, <name><surname>Dempsey</surname><given-names>D</given-names></name>, <name><surname>Jacob</surname><given-names>P</given-names><suffix>3rd</suffix></name>, <name><surname>Aziziyeh</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Reproducibility of the nicotine metabolite ratio in cigarette smokers</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2012</year>;<volume>21</volume>(<issue>7</issue>):<fpage>1105</fpage>&#x02013;<lpage>14</lpage>. Epub 2012/05/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1055-9965.EPI-12-0236">10.1158/1055-9965.EPI-12-0236</ext-link></comment>
; PubMed Central PMCID: PMC3392523.<pub-id pub-id-type="pmid">22552800</pub-id></mixed-citation></ref><ref id="pone.0128109.ref036"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Zhu</surname><given-names>AZ</given-names></name>, <name><surname>Zhou</surname><given-names>Q</given-names></name>, <name><surname>Cox</surname><given-names>LS</given-names></name>, <name><surname>Ahluwalia</surname><given-names>JS</given-names></name>, <name><surname>Benowitz</surname><given-names>NL</given-names></name>, <name><surname>Tyndale</surname><given-names>RF</given-names></name>. <article-title>Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>8</issue>):<fpage>e70938</fpage> Epub 2013/08/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0070938">10.1371/journal.pone.0070938</ext-link></comment>
; PubMed Central PMCID: PMC3732272.<pub-id pub-id-type="pmid">23936477</pub-id></mixed-citation></ref><ref id="pone.0128109.ref037"><label>37</label><mixed-citation publication-type="other">Chen LS, Bloom AJ, Baker TB, Smith SS, Piper ME, Martinez M, et al. Pharmacotherapy Effects on Smoking Cessation Vary with Nicotine Metabolism Gene (CYP2A6). Addiction. 2013. Epub 2013/09/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/add.12353">10.1111/add.12353</ext-link></comment>
.<pub-id pub-id-type="pmid">24033696</pub-id></mixed-citation></ref><ref id="pone.0128109.ref038"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Jacob</surname><given-names>P</given-names><suffix>3rd</suffix></name>, <name><surname>Yu</surname><given-names>L</given-names></name>, <name><surname>Duan</surname><given-names>M</given-names></name>, <name><surname>Ramos</surname><given-names>L</given-names></name>, <name><surname>Yturralde</surname><given-names>O</given-names></name>, <name><surname>Benowitz</surname><given-names>NL</given-names></name>. <article-title>Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity</article-title>. <source>J Chromatogr B Analyt Technol Biomed Life Sci</source>. <year>2011</year>;<volume>879</volume>(<issue>3&#x02013;4</issue>):<fpage>267</fpage>&#x02013;<lpage>76</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jchromb.2010.12.012">10.1016/j.jchromb.2010.12.012</ext-link></comment>
; PubMed Central PMCID: PMC3050598.<pub-id pub-id-type="pmid">21208832</pub-id></mixed-citation></ref><ref id="pone.0128109.ref039"><label>39</label><mixed-citation publication-type="other">Tanner J, Novalen M, Jatlow P, Huestis M, Murphy S, Kaprio J, et al. Nicotine Metabolite Ratio (3-hydroxycotinine/cotinine) in Plasma and Urine by Different Analytical Methods and Laboratories: Implications for Clinical Implementation. Cancer Epidemiol Biomarkers Prev. 2015;In press.</mixed-citation></ref><ref id="pone.0128109.ref040"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Saccone</surname><given-names>NL</given-names></name>, <name><surname>Wang</surname><given-names>JC</given-names></name>, <name><surname>Breslau</surname><given-names>N</given-names></name>, <name><surname>Johnson</surname><given-names>EO</given-names></name>, <name><surname>Hatsukami</surname><given-names>D</given-names></name>, <name><surname>Saccone</surname><given-names>SF</given-names></name>, <etal>et al</etal>
<article-title>The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans</article-title>. <source>Cancer research</source>. <year>2009</year>;<volume>69</volume>(<issue>17</issue>):<fpage>6848</fpage>&#x02013;<lpage>56</lpage>. Epub 2009/08/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/0008-5472.CAN-09-0786">10.1158/0008-5472.CAN-09-0786</ext-link></comment>
; PubMed Central PMCID: PMC2874321.<pub-id pub-id-type="pmid">19706762</pub-id></mixed-citation></ref><ref id="pone.0128109.ref041"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Amos</surname><given-names>CI</given-names></name>, <name><surname>Wu</surname><given-names>X</given-names></name>, <name><surname>Broderick</surname><given-names>P</given-names></name>, <name><surname>Gorlov</surname><given-names>IP</given-names></name>, <name><surname>Gu</surname><given-names>J</given-names></name>, <name><surname>Eisen</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1</article-title>. <source>Nat Genet</source>. <year>2008</year>;<volume>40</volume>(<issue>5</issue>):<fpage>616</fpage>&#x02013;<lpage>22</lpage>. Epub 2008/04/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.109">10.1038/ng.109</ext-link></comment>
; PubMed Central PMCID: PMC2713680.<pub-id pub-id-type="pmid">18385676</pub-id></mixed-citation></ref><ref id="pone.0128109.ref042"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Munafo</surname><given-names>MR</given-names></name>, <name><surname>Timofeeva</surname><given-names>MN</given-names></name>, <name><surname>Morris</surname><given-names>RW</given-names></name>, <name><surname>Prieto-Merino</surname><given-names>D</given-names></name>, <name><surname>Sattar</surname><given-names>N</given-names></name>, <name><surname>Brennan</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure</article-title>. <source>J Natl Cancer Inst</source>. <year>2012</year>;<volume>104</volume>(<issue>10</issue>):<fpage>740</fpage>&#x02013;<lpage>8</lpage>. Epub 2012/04/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jnci/djs191">10.1093/jnci/djs191</ext-link></comment>
; PubMed Central PMCID: PMC3352832.<pub-id pub-id-type="pmid">22534784</pub-id></mixed-citation></ref><ref id="pone.0128109.ref043"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Keskitalo</surname><given-names>K</given-names></name>, <name><surname>Broms</surname><given-names>U</given-names></name>, <name><surname>Heliovaara</surname><given-names>M</given-names></name>, <name><surname>Ripatti</surname><given-names>S</given-names></name>, <name><surname>Surakka</surname><given-names>I</given-names></name>, <name><surname>Perola</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Association of serum cotinine level with a cluster of three nicotinic acetylcholine receptor genes (CHRNA3/CHRNA5/CHRNB4) on chromosome 15</article-title>. <source>Human molecular genetics</source>. <year>2009</year>;<volume>18</volume>(<issue>20</issue>):<fpage>4007</fpage>&#x02013;<lpage>12</lpage>. Epub 2009/07/25. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/hmg/ddp322">10.1093/hmg/ddp322</ext-link></comment>
; PubMed Central PMCID: PMC2748889.<pub-id pub-id-type="pmid">19628476</pub-id></mixed-citation></ref><ref id="pone.0128109.ref044"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Zhu</surname><given-names>AZ</given-names></name>, <name><surname>Renner</surname><given-names>CC</given-names></name>, <name><surname>Hatsukami</surname><given-names>DK</given-names></name>, <name><surname>Benowitz</surname><given-names>NL</given-names></name>, <name><surname>Tyndale</surname><given-names>RF</given-names></name>. <article-title>CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users</article-title>. <source>Addiction</source>. <year>2013</year>;<volume>108</volume>(<issue>10</issue>):<fpage>1818</fpage>&#x02013;<lpage>28</lpage>. Epub 2013/05/23. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/add.12250">10.1111/add.12250</ext-link></comment>
; PubMed Central PMCID: PMC3775934.<pub-id pub-id-type="pmid">23692359</pub-id></mixed-citation></ref><ref id="pone.0128109.ref045"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Wassenaar</surname><given-names>CA</given-names></name>, <name><surname>Dong</surname><given-names>Q</given-names></name>, <name><surname>Wei</surname><given-names>Q</given-names></name>, <name><surname>Amos</surname><given-names>CI</given-names></name>, <name><surname>Spitz</surname><given-names>MR</given-names></name>, <name><surname>Tyndale</surname><given-names>RF</given-names></name>. <article-title>Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk</article-title>. <source>J Natl Cancer Inst</source>. <year>2011</year>;<volume>103</volume>(<issue>17</issue>):<fpage>1342</fpage>&#x02013;<lpage>6</lpage>. Epub 2011/07/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jnci/djr237">10.1093/jnci/djr237</ext-link></comment>
; PubMed Central PMCID: PMC3168937.<pub-id pub-id-type="pmid">21747048</pub-id></mixed-citation></ref><ref id="pone.0128109.ref046"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Brennan</surname><given-names>P</given-names></name>, <name><surname>Hainaut</surname><given-names>P</given-names></name>, <name><surname>Boffetta</surname><given-names>P</given-names></name>. <article-title>Genetics of lung-cancer susceptibility</article-title>. <source>Lancet Oncol</source>. <year>2011</year>;<volume>12</volume>(<issue>4</issue>):<fpage>399</fpage>&#x02013;<lpage>408</lpage>. Epub 2010/10/19. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1470-2045(10)70126-1">10.1016/S1470-2045(10)70126-1</ext-link></comment>
.<pub-id pub-id-type="pmid">20951091</pub-id></mixed-citation></ref><ref id="pone.0128109.ref047"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Spitz</surname><given-names>MR</given-names></name>, <name><surname>Amos</surname><given-names>CI</given-names></name>, <name><surname>Bierut</surname><given-names>LJ</given-names></name>, <name><surname>Caporaso</surname><given-names>NE</given-names></name>. <article-title>Cotinine conundrum&#x02014;a step forward but questions remain</article-title>. <source>J Natl Cancer Inst</source>. <year>2012</year>;<volume>104</volume>(<issue>10</issue>):<fpage>720</fpage>&#x02013;<lpage>2</lpage>. Epub 2012/04/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jnci/djs211">10.1093/jnci/djs211</ext-link></comment>
; PubMed Central PMCID: PMC3352835.<pub-id pub-id-type="pmid">22534783</pub-id></mixed-citation></ref><ref id="pone.0128109.ref048"><label>48</label><mixed-citation publication-type="journal">
<name><surname>Zhu</surname><given-names>AZ</given-names></name>, <name><surname>Renner</surname><given-names>CC</given-names></name>, <name><surname>Hatsukami</surname><given-names>DK</given-names></name>, <name><surname>Swan</surname><given-names>GE</given-names></name>, <name><surname>Lerman</surname><given-names>C</given-names></name>, <name><surname>Benowitz</surname><given-names>NL</given-names></name>, <etal>et al</etal>
<article-title>The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source>. <year>2013</year>;<volume>22</volume>(<issue>4</issue>):<fpage>708</fpage>&#x02013;<lpage>18</lpage>. Epub 2013/02/02. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1055-9965.EPI-12-1234-T">10.1158/1055-9965.EPI-12-1234-T</ext-link></comment>
; PubMed Central PMCID: PMC3617060.<pub-id pub-id-type="pmid">23371292</pub-id></mixed-citation></ref></ref-list></back></article>